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Abstract 
 
Growth factor receptors have significant effects on various normal function of body such as 
cell proliferation, differentiation and apoptosis. They are also involved in neuronal function 
and dysfunction, cardiovascular diseases, and malignancies. Recently, multiple G protein-
coupled receptors (GPCRs) have been shown to transactivate receptor tyrosine kinases 
(RTKs). Since both classes of receptors have complicated downstream cascades individually, 
understanding the signaling differences between GPCR-induced growth factor receptor 
transactivation and direct ligand activation is an important challenge. To clarifying this 
phenomenon we investigated the phosphorylation profile and downstream effectors of 
ligand-activated vs. transactivated PDGFβ receptors. Dopamine receptors (one of the 
receptors of the GPCRs family) were used to compare the PDGFβ receptor phosphorylation 
and activity during direct activation and transactivation. Dose-response and time-course data 
between these two stimuli were evaluated. Furthermore, the phosphorylation site profiles and 
the intracellular signaling pathways of PDGFβ receptor after direct activation and 
transactivation were examined. In addition, possible synergic effects between transactivation 
and direct activation were explored. The results of this project showed that the 
phosphorylation profile and downstream effectors of ligand activated receptors versus 
transactivated receptors are different. Our data indicated that transactivation-induced 
pathways are more involved in survival and proliferation effects compared to ligand 
activation. This research answered basic questions about transactivation phenomena and 
proposes that these transactivation pathways could be exploited as a therapeutic approach for 
neurodegenerative diseases.  
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 Chapter 1
Introduction 
 
1.1 Cell-to-cell communication 
Cell-to-cell communication in a multicellular organism is essential for life. This communication 
leads to various physiological activities that are important in proliferation, differentiation, 
migration, and apoptosis of cells. Different signal transduction pathways are involved to balance 
and maintain these activities. Different classes of receptors regulate signal transduction: 
transmembrane receptors with extracellular, transmembrane, and intracellular domains; 
intracellular receptors such as steroid/thyroid hormone receptors; and peripheral membrane 
proteins, with a loose attachment to the cell membrane and without any attachment into the lipid 
bilayer membrane. Extracellular signaling molecules such as neurotransmitters, growth factors, 
hormones, and cytokines transfer their signal into the cells. Five transmembrane signaling 
mechanisms for transferring signal from outside the cells to inside the cells are described 
[Figure  1.1]: intracellular receptors for lipid-soluble molecules, ligand-regulated transmembrane 
enzymes, ligand-regulated tyrosine kinase, ligand- and voltage-gated channels, G-proteins and 
second messengers [1]. The cell surface receptors and their downstream cascades are of interest 
since they play key roles in modulating cell physiology. 
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Figure  1.1 Transmembrane signaling mechanisms 
1. Intracellular receptors stimulate or inhibit specific gene transcription after activation and translocation to the 
nucleus. 2. Receptor tyrosine kinase 3. Cytokine receptors are transmembrane receptors that ligand binding results in 
activating of Janus-kinase (JAK) family associated with the receptor. These kinases phosphorylate tyrosine residues 
on the cytoplasmic part of the receptors and consequently activate STATs that results in gene transcription. 4. 
ligand-gated channels act by controlling the flow of the ions through ion channel such as N-methyl-D-aspartate 
(NMDA) receptors and GABA receptors 5.G-protein coupled receptors [1]. 
 
1.2 G-protein-coupled receptors (GPCRs) 
Guanine nucleotide binding protein-coupled receptors, or G-protein-coupled receptors (GPCRs), 
comprise a large family of receptors known as seven-transmembrane domain receptors or 
serpentine receptors because they pass and wave through the cell membrane seven times. These 
receptors are the largest family of cell surface receptors, and their genes constitute 5% of the 
human genome [2]. They also represent the largest classes of current drug targets [3]. GPCRs 
mediate the majority of cellular responses to chemokines, neurotransmitters including dopamine 
and serotonin (5-HT), hormones, lipids, and sensory stimuli such as light [3]. GPCRs contain an 
extracellular N-terminal domain, a 7 α-helice transmembrane region (TM-I to TM-VII), and an 
intracellular C-terminal domain. The transmembrane region is connected by three intracellular 
(IL1-2-3) and three extracellular (EL1-2-3) loops. The intracellular domain contains several 
serine and threonine residues, and their hydroxyl (OH) groups can be phosphorylated. 
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Intracellular domain phosphorylation may regulate activity, intracellular signaling, and receptor 
desensitization. The G-proteins themselves interact with the loop between transmembrane V and 
VI in the cytoplasmic portion of the receptor.  
 
The heterotrimeric G-proteins are composed of α  β  and γ subunits. In humans  sixteen Gα genes 
encode 23 known Gα isoforms [2]. G protein heterotrimers are identified by the α subunit. Based 
on sequence similarity  Gα proteins are divided into four classes including Gα(s/olf)  Gα(i1/i2/i3/o/t-
cone/gust/z), Gα(q/11/14/16)  and Gα(12/13) [4,5]. Six Gβ  and eleven Gγ have also been identified [6] and 
this leads to various combination of Gβγ [2]. The Gα subunit binds to GDP and Gβγ. The Gβγ 
complex facilitates the association of Gα to the intracellular part of the GPCR. In addition  Gβγ 
inhibits the release of GDP from Gα and acts as a guanine nucleotide dissociation inhibitor 
(GDI) [2]. 
 
Since GPCRs do not have intrinsic enzymatic activity, binding of a ligand to the extracellular 
domain of GPCR triggers a conformational change in the receptors; this transduces the ligand‟s 
message mechanically to the heterotrimeric G-proteins on the intracellular side of the protein and 
leads to different downstream signaling cascades [7]. Ligand binding to the receptor acts as a 
guanine nucleotide exchange factor (GEF) because it promotes the release of GDP and the 
binding of GTP on the Gα subunit. GTP binding promotes the dissociation of Gα from Gβγ  and 
then, both GTP-Gα and Gβγ can activate effectors and alter second messenger levels including 
cyclic adenosine-3,5-monophosphate (cAMP), calcium, or phosphoinositides [1]. Each Gα and 
Gβγ subunits have specific pathways they activate and regulate [Table  1.1]. The intrinsic 
guanosine triphosphatase (GTPase) activity of the Gα subunit inactivates Gα by hydrolysing 
GTP back to GDP. Inactive GDP-Gα re-associates with Gβγ complex and the receptor [8]. This 
is the primary mechanism for making GPCR activation a transient process.  
 
Often, stimulation of GPCRs results in a rapid loss of subsequent responsiveness. G-protein 
coupled receptor kinases (GRKs) can regulate the activation of GPCRs [9]; activated receptors 
stimulate GRKs and in turn GRKs phosphorylate serine residues of the carboxyl terminal of the 
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GPCRs [9]. Phosphoserines increase affinity of the receptor to β-arrestin proteins. β-arrestins 
attenuate the ability of the receptor to complex with Gαs and decreases receptor responses to 
agonists; a process called desensitization [10]. Dissociation of the agonist from the receptor 
terminates GRK activity, and phosphatases can reverse the desensitization [9]. For some GPCRs, 
β-arrestins speed up receptor endocytosis [10]. Endocytosis of receptors concomitant with 
dephosphorylation of the receptors by phosphatase results in dephosphorylated receptors on 
endosomes that may be recycled back to the membrane [9,10]. However, excessive exposure of 
the receptors to their ligand leads to endocytosis, transfer to lysosomes, and degradation of the 
receptors. Thus, endocytosis can restore or attenuate cellular responses to the agonist by rapid 
recycling or degradation of the receptor, respectively [9,10], depending on duration of the 
receptor exposure to ligand, the number of ligands available for activation of receptors, the 
particular receptors that are activated  and the affinity of β-arrestins for phosphorylated receptors 
[10]. Recently, researchers have suggested that GPCR endocytosis is not only a mechanism for 
signal desensitization, but also a mechanism for additional signal transduction pathways [11]. 
 
Two of the three major intracellular signaling pathways have been described: the classical 
pathway, ligand binding to the receptor stimulates various G-protein-effectors [7] and the β-
arrestin pathway, the phosphorylation of the C-terminal domain of the GPCR via GRKs 
stimulates ligand-regulating scaffolds through β-arrestin and modulates GPCRs function. A third 
pathway, the transactivation pathway, involves the activation of GPCRs to increase receptor 
tyrosine kinase (RTK) signaling [8]. The focus of this thesis is to examine the scope of this novel 
GPCR signaling mechanism, termed transactivation, where the binding of the ligand to GPCRs 
activates downstream cascades that ultimately lead to the activation of receptor tyrosine kinases 
(RTKs) [8]. 
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Table  1.1 Gα‎subunits‎and‎Gβγ‎specific‎pathways 
 Type Pathways References 
1 Gαs 
Stimulates AC pathway and cAMP production [12] 
2 Gαi/o 
Inhibits AC and cAMP production [13] 
3 Gαq  Gα11, 
Gα14  Gα16 
Stimulate PLC pathway 
[14] 
4 Gαolf 
Gαgust 
Stimulate odorant and testant GPCRs respectively 
[15-17] 
5 Gαt 
Control phototransduction [17] 
6 Gα12 ,Gα13 
Regulate G-protein RhoA and stimulate PDZ-Rho guanine-
nucleotide exchange factors (PDZ-RhoGEF) 
[2] 
7 Gβγ-
complex 
1. Inhibits the release of GDP from Gα and acts as a guanine 
nucleotide dissociation inhibitor (GDI) 
2. Regulate K+ and Ca+2 channels.  
3. Regulate kinase and small G-protein including 
Phosphoinositide-3 kinase-γ (PI3 Kγ) 
4.Other various regulation pathways have been considered for 
downstream activation of Gβγ 
[2] 
 
1.2.1 Dopamine and dopamine receptors 
Dopamine (3-hydroxytyramine) is a metabolite of the amino acid tyrosine. Dopamine itself is a 
precursor for other neurotransmitter such as noradrenaline/norepinephrine and 
adrenaline/epinephrine [18]. Because the dopaminergic system regulates major mammalian basic 
brain functions, it is associated with many neurologic and psychiatric disorders. Dysregulation of 
the dopaminergic signal system leads to several pathological and physiological abnormalities 
such as Parkinson‟s disease  schizophrenia  Huntington‟s disease  Tourette‟s syndrome  
depression, and attention-deficit hyperactivity disorder (ADHD) [18-20]. Additionally, an 
irregular increase in dopamine signal transduction is involved in drug misuse and addiction [21]. 
 
Dopamine receptors are GPCRs that control and modulate different intracellular signal 
transduction pathways. Dopamine exerts its effects via subsequent downstream intracellular 
cascades such as activating and inhibiting the adenylyl cyclase (AC) pathway and cAMP 
production or stimulating protein kinase C (PKC) signaling. Dopamine receptors form two 
different families: D1-like receptors (D1 and D5) and D2-like receptors (D2, D3, and D4). These 
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two families interact with various intracellular downstream cascades; have different regulatory 
mechanisms, neuronal networks localizations, evolutionary origins, and structures [22]. These 
two classes are primarily differentiated by their effects on adenylyl cyclase [23]. Gαs/olf is 
activated by D1-family dopamine receptors to stimulate cAMP production via adenylyl cyclase, 
whereas Gαi/o couples to the D2-family dopamine receptors and inhibits adenylyl cyclase activity 
[18,22]. In addition to the inhibition of adenylyl cyclase, D2-family dopamine receptors also 
activate the Na
+
/H
+ 
exchanger, open K
+
 channels, increase Cl
-
 influx, change neuronal 
morphology, promote mitogenesis, induce the release of arachidonic acid, increase 
phosphoinositide hydrolysis, inhibit Ca
+2
 channel, and inhibit apoptosis [24]. Blocking D2-family 
dopamine receptors is of interest for antipsychotic drug development [20], whereas dopamine 
D2/D3 receptor agonists are widely used in Parkinson‟s disease. 
1.2.2 Serotonin and serotonin receptors 
The monoamine neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) is involved in a wide 
variety of physiological effects in the CNS, the peripheral nervous system (PNS), and in 
nonneuronal tissues. It plays roles in the regulation of mood, cognition, perception, memory, 
aggression, feeding behaviour, sleep and wake cycles, pain, and anxiety [25,26]. Mammals 
express seven different receptor subtypes (5-HT1–5-HT7) and many subtypes have multiple 
isoforms. All serotonin receptor subtypes are GPCRs except 5-HT3, which is a ligand-gated ion 
channel permeable to calcium, sodium, and potassium [26]. 5-HT4, 5-HT6, and 5-HT7 are 
coupled to Gαs; 5-HT1 and 5-HT5 are coupled to Gα i/o; and 5-HT2 is coupled to Gαq [27]. 
1.3 Receptor tyrosine kinases (RTKs) 
Receptor tyrosine kinases (RTKs), also called growth factor receptors, bind protein growth factor 
ligands and initiate a variety of intracellular signaling pathways. RTKs consist of an extracellular 
Ig-ligand-binding domain, a single transmembrane domain, and an intracellular tyrosine kinase 
domain. Ligand binding to extracellular domains initiates a dimerization process and triggers 
cross-autophosphorylation of different intracellular tyrosine residues via the intrinsic tyrosine 
kinase activity of RTKs. These phosphorylation sites become docking sites for adaptor 
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molecules that in turn activate different downstream intracellular cascades that include 
RAS/MAPK/ERK, PI3-kinase/Akt  and PLCγ pathways [28]. Several signaling cascades 
downstream of RTKs ultimately exert phenotypic responses including cell growth, proliferation, 
differentiation, and survival.  
1.3.1 Platelet-derived growth factors and their receptors  
The platelet-derived growth factor (PDGF) was first purified from platelets. It plays a key role in 
stimulating growth and migration in platelets, fibroblasts, smooth muscle cells, neurons, and 
several other cell types. PDGF also has various physiological effects such as augmentation of 
immune responses and immune regulation, inflammation, tumorigenesis, and wound healing [29-
31]. In the central nervous system (CNS) it exerts neurotrophic effects. Specifically, it has 
important neurotrophic effects in regulating neuronal proliferation and growth [30] as well as in 
stimulating and modulating neurogenesis and synaptogenesis [32]. The dimeric polypeptide 
molecules of the PDGF ligand family consist of five heterodimeric and homodimeric subtypes: 
PDGF-AA, PDGF-BB, PDGF-AB [33], PDGF-CC [34], and PDGF-DD [35]. Since the 
endogenous expression of PDGF-B and PDGF-A rarely overlaps, the presence of PDGF-AB is 
infrequent, and it has only been found in human platelets [36]. PDGF-A and PDGF-B have pro-
domain on their N-terminus; intracellular furin or proprotein convertases removes this pro-
domain. This process is important for ligand binding ability [36]. PDGF-C and PDGF-D are not 
similarly processed and they are secreted as latent ligands. Tissue plasminogen activator (tPA) 
proteolytically dissociates the growth factor domain of PDGF-C and PDGF-D from the CUB-
domain in extracellular space in order to activate them in plasma and tissue [37]. 
 
All PDGF subtypes have a conserved homology domain that is involved in dimer formation 
through a disulfide bridge. The mature form of PDGF-A and PDGF-B consists of 100 amino 
acids with a 60% similar amino acid sequence and eight conserved cysteine residues in each 
chain. The second and fourth cysteines are involved in intermolecular disulfide bonds, and the 
rest are involved in intramolecular disulfide bonds [38,39]. The vascular endothelial growth 
factor (VEGF) is related both structurally and functionally to PDGF [37]. Previously, scientists 
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believed that each growth factor family had an affinity to bind with its own receptors; however, 
recent studies have shown that VEGF-A can bind and signal through PDGF receptors in bone-
marrow-derived mesenchymal stem cells [40,41]. There is also similarity in the protein structure 
of PDGF-BB with VEGF, NGF, and TGF-B.  
 
The five dimeric PDGF isoforms induce various intracellular signaling cascades via two cell 
surface RTKs: PDGFα receptors and PDGFβ receptors [28]. Post-translational modification 
(glycosylation) is required for cell surface expression of both PDGFα receptors and PDGFβ 
receptors [143,177]. Three different types of receptor homo- or hetero-dimerization may occur 
after ligand binding to the receptor based on the ligand configuration and the receptor expression 
[42]. Dimerization of the receptor via its ligands leads to cross-autophosphorylation of different 
intracellular tyrosine residues and activation of the receptor. Most of the phosphorylation sites of 
PDGF receptors are identified outside the kinase region; except Tyr857 that is placed in the 
kinase domain of the PDGFβ receptors [43]. These phosphorylation sites become docking sites 
for mediators that lead to different downstream intracellular cascades. Each of the five PDGF 
isoforms has a specific affinity to each of PDGF receptors: PDGF-AA, -BB, -AB, and -CC bind 
to PDGFα receptors  whereas PDGF-BB (high affinity) and PDGF-DD (low affinity) can bind to 
PDGFβ receptors. PDGFαβ receptors heterodimers bind PDGF-BB, -AB, -CC, and -DD [44]  
[Figure  1.2].  
 
PDGF receptors consist of five extracellular immunoglobulin-like (Ig-like) domains and an 
intracellular tyrosine kinase domain [36]. The extracellular domain is separated from 
intracellular domain by a transmembrane domain. The three outermost Ig domains are involved 
in ligand binding, and a direct receptor-receptor interaction occurs in the fourth immunoglobulin 
domain [28]. Although ligand binding to the receptor is essential for receptor dimerization, at a 
high level of receptor expression, dimerization and autophosphorylation of the receptor may 
occur independent of ligand binding, i.e. PDGF receptor may spontaneously dimerize at high 
local concentrations [29]. The intracellular domain of the receptor consists of three parts: a 
juxtamembrane domain without enzyme activity, a tyrosine kinase domain, and a C-terminal 
  9 
domain. The juxtamembrane domain and tyrosine kinase domain in PDGFα receptors and 
PDGFβ receptors share 80% similarity in their amino acids sequence; the kinase domain is 
divided to two separated parts by the insertion of almost 100 amino acids called the kinase insert 
[43]. In contrast, the extracellular domain and C-terminus domain share just 30% amino acid 
similarity.    
 
 
 
Figure  1.2 The PDGF-PDGF receptor interaction in vitro 
There is a lack of evidence for interaction between some of the PDGF-PDGF receptors in vivo. The current in vivo 
evidence supports only the interaction between PDGF-AA and PDGF-CC with PDGFα receptors  and PDGF-BB 
and PDGF-DD with PDGFβ receptors [36]. 
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1.3.1.1 PDGF and PDGF receptor expression patterns 
PDGF and PDGF receptor genes are located on different chromosomes, and they have 
independent transcriptional regulation. PDGF is secreted as a paracrine growth factor but in 
tumors may act as an autocrine factor. Expression of PDGF is dependent on different stimuli 
such as, growth factors, hypoxia, inflammation, cytokines, and thrombin. Expression of PDGF 
receptors is also dynamic; TGF-α  estrogen, fibroblast growth factor 2 (FGF-2), 
lipopolysaccharide, tumor necrosis factor, and interleukin-1 (IL-1) can induce receptor 
expression [36,42]. The expression of PDGF and PDGF receptors is modulated temporally 
during development [36].  
 
PDGFs and VEGFs play a key role in hematopoietic development, neurogenesis, and 
neuroprotection [36]. PDGF-A is produced in neurons and glial cells in the central nervous 
system [45], and PDGF-B is expressed exclusively in the vascular endothelial cells and 
megakaryocytes, and in the nervous system where it is produced in the soma, principal dendrites, 
and axons of the neuron [46]. PDGF-A has mitogenic functions for glial cells and regulates 
oligodendrocyte development. PDGF-B, but not PDGF-A, promotes neurite outgrowth, neuronal 
survival, and gene expression in human dopaminergic neurons during embryonic development 
and, to a lesser extent, in adult brain cells [30]. PDGF-A and PDGF-C are produced in muscle, 
epithelial cells, and neuronal progenitors. There is not sufficient evidence for PDGF-D 
expression; however, it has been shown in a certain location of fibroblasts and SMCs [36].  
 
PDGFα receptors and PDGFβ receptors are expressed in CNS and throughout many peripheral 
tissue types [30,36]. PDGFα receptors are expressed in glial cells but not neurons  
oligodendrocyte progenitors (OPs), mesenchymal progenitors in the lungs, intestine, and skin; 
whereas  PDGFβ receptors are expressed predominantly in neurons, pericytes, mesenchyme, and 
vascular SMCs (vSMCs) [47,48]. PDGF receptors have been shown to exert neurotrophic effects 
on both the dopaminergic and GABAergic neurons [49]. Furthermore, they have modulatory 
effects on N-methyl-D-aspartate receptors (NMDARs), which are important in learning, memory 
and synaptic plasticity, i.e. long-term potentiation (LTP) or depression (LTD) [49]. The 
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expression patterns of PDGFα and PDGFβ receptors are associated with different responses; 
transcriptional regulation of these receptor genes prevents redundancy of their expression. 
PDGFα receptor knock-out animals showed the normal phenotypes because PDGFβ receptors 
can substitute PDGFα receptor signaling. However  in the reverse knock-out animals  PDGFα 
receptors can only partially compensate for the lack of PDGFβ receptors. Thus  the specificity of 
PDGF receptors signaling is dependent on cell type, specific expression of the receptors, and the 
distinct downstream cascades of each of these receptors [50]. In the following sections, we will 
focus on PDGF-BB and PDGFβ receptors because PDGFβ receptors are expressed mainly in 
neuron cells  whereas PDGFRα is expressed mainly in support cells. 
1.3.1.2 Downstream pathways of PDGF receptors 
PDGF ligand binding to their receptors induces dimerization that brings the receptor kinases 
close to each other and leads to auto- and trans-phosphorylation of intracellular tyrosine residues 
of PDGF receptors. The first three Ig-like domains contribute to ligand binding and the fourth  
Ig-like domain is essential for dimerization of the receptors. There is a debate whether the 
dimerization of the receptors is sufficient to activate the receptors or if additional conformational 
changes of the receptors by ligands are required. The review by Jiang and Hunter highlighted 
that unliganded dimer receptors can be formed, but the ligand binding is essential for full 
activation [51]. Autophosphorylation of the receptor regulates the catalytic activity of the 
receptor intracellular kinase domain. The auto-phosphorylation sites in PDGF receptors belong 
to two different groups. The first group is tyrosine residues located at the activation loop of the 
kinase domain, and the phosphorylation of these tyrosine residues increases the kinase activity. 
In PDGFβ receptors, the tyrosine that is phosphorylated in the kinase domain is tyrosine 857 and 
its mutation results in lower kinase activity of the PDGFβ receptor [52]. Tyr857 has an important 
autoinhibitory role in its unphosphorylated state for PDGFβ receptors. Binding of the ligand to 
the receptor results in conformational changes in that area of the receptor and allows for intrinsic 
kinase activity to phosphorylate Tyr857 and unlock the kinase, thereby resulting in full 
enzymatic activity [53]. The second group of tyrosine residues are located outside the kinase 
domains in the kinase insert; phosphorylation of these tyrosine residues result in docking sites for 
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a number of known effectors containing Src homology 2 (SH2) domains, phosphotyrosine 
binding (PTB) domains, and pleckstrin homology (PH) domains [28]. 
 
There are 15 tyrosine residues in the intracellular, non-catalytic part of PDGFβ receptors  11 of 
these 15 tyrosine residues are autophosphorylation sites for the receptors [28]. Specificity for 
phosphotyrosine residues in the recognition and binding of SH2 domains is achieved by specific 
amino acids surrounding them [54]. These phosphorylated tyrosine residues can bind to various 
signal transduction effectors. Some tyrosines on the receptor are phosphorylated by kinases other 
than the receptor itself such as Tyr934 in PDGFβ receptors that is phosphorylated by Src 
[Table  1.2]. 
 
Tyrosine phosphorylation sites of PDGFβ receptors have two responsibilities: controlling the 
activity of the kinase and producing docking sites for signal transduction molecules, such as 
effectors or adaptor proteins. Protein-protein interactions and protein-lipid interactions play a key 
role in simulating the downstream signaling cascades of PDGF receptors. Important domains for 
mediating the activation of downstream effectors include SH2 and PTB domains that recognize 
phosphorylated tyrosine residues, PH domains that recognize membrane phospholipid residues, 
SH3 and PDZ domains that recognize proline-rich regions, and C-terminal-specific sequences 
[28]. To increase the strength of an effector interaction, two domains may interact with two 
distinct sites of this effector.  
 
SH2 domains are the most important domains for recognizing phosphotyrosine residues. Proteins 
containing SH2 domains can be separated into three different groups: First, molecules with 
intrinsic enzyme activity including the Src family of tyrosine kinase, the tyrosine phosphatase 
SHP-2, phospholipase Cγ (PLCγ)  and the GTPase activating protein (GAP) for Ras. Second, 
molecules acting as adaptor proteins without enzyme activity including Shc, Grb7, Grb2, Nck, 
Crk, the p85 regulatory subunit of phosphatidylinositol 3 kinase (PI3-kinase). Third, molecules 
that act as transcription factors such as signal transducers and activators of transcription (Stats) 
[54].  
  13 
 
Table  1.2 Tyrosine‎phosphorylation‎sites‎of‎PDGFβ‎receptors and their physiological effects 
Tyrosine 
Phosphorylation 
sites 
The effector The physiological role References 
Tyr579 
Src 
 
Shc 
 
Stat5 
Src: Mitogenicity, cell cycle progression to the S phase, 
DNA synthesis, possible negative regulation of cytoskeletal 
rearrangements and cellular movement 
Shc: Grb2/Ras/MAPK pathway 
Stat5: Gene expression related to proliferation, differentiation 
and apoptosis 
[28,53,55] 
Tyr581 
Src 
 
 
Stat5 
 
Src: Mitogenicity, cell cycle progression to the S phase, 
DNA synthesis, possible negative regulation of cytoskeletal 
rearrangements and cellular movement that are induced via 
PDGF 
Stat5: Gene expression related to proliferation, differentiation 
and apoptosis 
[28,55] 
Tyr716 
Grb2 
 
Grb7 
Grb2-Sos/Ras/MAPK pathway 
 
Grb7: Involved in migration of neuronal cells in embryo 
 
[28,53,58]  
Tyr740 
PI3-kinase 
Shc 
PI3-kinase:Akt/PKB pathway 
Shc: Grb2/Ras/MAPK pathway 
[28,53,56] 
Tyr751 
PI3-kinase 
Shc 
Nck 
PI3-kinase: Akt/PKB pathway 
Shc: Grb2/Ras/MAPK pathway 
Nck: Proliferation (overexpression of Nck lead to 
transformation) 
[28,53,56] 
Tyr763 
SHP-2 
 
SHP-2: Negatively: dephosphorylates autophosphorylation site 
Tyr740/Tyr751/Tyr771 
Positively: Grb2/Ras/MAPK pathway, Src/MAPK pathway 
[28] 
Tyr771 
GTPase of Ras 
Shc 
GAP :Negative regulation of Ras 
Shc: Grb2/Ras/MAPK pathway 
[28,53] 
Tyr775 
Grb2 
Grb7 
Stat5 
Grb2-Sos/Ras/MAPK pathway 
Grb7: Involved in migration of neuronal cells in embryo 
Stat5: Activation and translocation to nucleus leads to gene 
expression related to proliferation, differentiation and apoptosis 
[28,58] 
 
Tyr857  
Regulation of receptor Kinase Activity 
(allows the access of PLCγ1 and GAP proteins and ATP to the 
active site of the receptor) 
[28,52] 
Tyr934  
Phosphorylated by Src, negatively regulate PDGF receptor-
induced motility by PLCγ pathway 
[53,57] 
Tyr1009 
SHP-2 
 
PLCγ1 
 
SHP-2: Negatively: dephosphorylates autophosphorylation site 
Tyr740/Tyr751/Tyr771 
Positively: Grb2/Ras/MAPK pathway,Src/MAPK pathway 
PLCγ1: Ca+2 signaling, mitagenicity and in some cell 
migration, inhibition of NMDA and GABAA receptors 
[28,53] 
Tyr1021 PLCγ1 
PLCγ1: Ca+2 signaling, mitagenicity and in some cell 
migration, inhibition of NMDA and GABAA receptors 
[53] 
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These interactions and processes initiate various signaling downstream pathways regulating cell 
growth, differentiation, migration, and survival [28]. Stimulation of PDGFβ receptors by    
PDGF-BB leads to an array of temporally regulated cellular responses that include: changes in 
cytoplasmic pH and an influx of intracellular Ca
+2 
[43], cytoskeleton rearrangement, actin stress 
fiber rearrangement, and cell membrane process formation [43], proliferation, differentiation, 
migration, cell survival, and specific patterns of gene regulation [43].  
1.3.1.2.1 Ras/MAPK/ERK pathway 
A group of serine/threonine kinases that stimulate proliferation, differentiation, apoptosis, and 
long-term potentiation is called the mitogen-activated protein kinase (MAPK) pathway. 
Typically, the MAPK pathway begins with the binding of the growth factor ligands to the PDGF 
receptors. This results in the docking of an SH2 domain-containing protein called growth factor 
receptor-bound protein 2 (Grb-2) that can bind directly or through additional adaptor proteins to 
the phosphorylated sites of the activated receptor. Grb2, a 24 kDa protein, is the major adaptor 
protein in growth factor receptor activation of Ras. It contains one SH2 domain that directly 
binds to phosphorylated Tyr716 and Tyr775 residues of the PDGFβ receptor. Grb2 can also bind 
to the PDGFβ receptor indirectly via other tyrosine phosphorylated proteins bound to PDGFβ 
receptor, such as the adaptor protein Shc or the tyrosine phosphatase SHP-2 [58]. SHP-2 binds to 
phosphorylated Tyr763 and Tyr1009, whereas Shc binds to several phosphorylated sites of 
PDGFβ receptor [59,60].  
 
The guanine nucleotide exchange factor (GEF), is called Son of Sevenless (Sos), can bind to the 
two SH3 domains of the Grb-2 protein. Activated Sos has the ability to bind to the membrane-
bound protein Ras and catalyzes its activation by promoting GDP for GTP exchange. This 
exchange leads to the activation of Ras that results in the stimulation of several downstream 
proteins. Ras proteins are essential components of signaling pathways that regulate cellular 
proliferation, differentiation, and apoptosis. Human Ras protein has four isoforms that show 
different biological functions and each of these Ras homologs participates in distinct signal 
transduction pathway [61]. GTPase-activating proteins such as GAPs; p120GAP, and 
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neurofibromin/NF1-GTPase, catalyze GTP hydrolysis are the effectors for inactivating Ras [62]. 
Activated Ras binds to effector proteins that eventually initiates downstream signaling cascades 
that results in programmed responses of the cell [61]. The cytosolic serine/threonine-protein 
kinase Raf is the best-characterized effector protein for Ras; other putative effectors include PI3-
kinase [62], RalGDS (a GEF for the Ras-related molecule Ral), RGL (a RalGDS-related 
molecule), MEK kinase, protein kinase C (PKC), Bcl-2, and JNK (the latter two are important in 
Ras regulation of apoptosis) [63,64]. Raf phosphorylates and activates dual-specificity kinase 
MAPK kinase, also called MEK [65]. Activated MEK phosphorylates extracellular signal-
regulated kinases (ERK1/2). Finally, activation of ERK1/2 results in stimulation of various 
cytoplasmic proteins including cytoplasmic phospholipase A2. The dimerized form of activated 
ERK1/2 can translocate into the nucleus, where the complex phosphorylates and activates 
transcription factors to induce gene transcription [66,67].  
 
The MAPK pathway can be divided into three different pathways in mammals: extracellular 
signal-regulated kinase ERK1/2, which has an important role in cell growth and differentiation 
[Figure  1.3]; C-Jun N-terminal kinases (JNKs) or stress activated protein kinase (SAPK), which 
plays a key role in cell transformation, apoptosis and stress responses; and finally, p38 MAPK, 
which has the similar functions as SAPK/JNKs [68]. Activation of JNKs by stress and 
inflammatory stimuli, cytokines, or UV light leads to phosphorylation of the transcription factor 
c-Jun at its N-terminal serine residue. The p38 pathway activates the serine/threonine-kinase 
MAPK-activated protein kinase (MAPKAPK) 2 and the transcription factor ATF-2. Ras/MAPK 
pathway regulation by negative feedback is essential for avoiding excessive and abnormal cell 
responses.  
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Figure  1.3 The classical pathway of MAPK, ERK1/2 pathway 
 
1.3.1.2.2 Src-family kinases  
Src-Family protein kinases (SFK) have been described as oncogenic proteins. They modulate 
various cellular functions such as proliferation, differentiation, survival, cell morphology, cell 
motility, and adhesion. Members of the Src family kinase belong to the tyrosine kinase family 
with molecular masses ranging from 53 kDa to 64 kDa. They have six different domains 
consisting of an N-terminal membrane association domain (14-carbon myristoyl group attached 
to an SH4 domain); an SH2 domain; an SH3 domain, a tyrosine kinase domain (catalytic domain 
or the SH1 domain); a C-terminal negative regulatory domain; and the unique segment (with the 
greatest sequence diversity and with multiple serine/threonine phosphorylation sites) 
[Figure  1.4]. Ten homologous proteins are included in the SFKs family: Src, Blk, Hck, Fyn, Fgr, 
Lck, Lyn, Yes, Yrk, and Frk subfamily proteins. Two important phosphorylation sites on Src 
family kinases are Tyr416 that promotes SFK activity when phosphorylated and Tyr527 inhibits 
SFK activity.  
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Figure  1.4 Structure of Src family kinase 
 
Src has a key role in many downstream signaling cascades of RTKs including PDGF receptors. 
Tyr579 and Tyr581 are the docking sites for Src on PDGFβ receptors and Tyr572 and Tyr574 
mediate binding of the Src to the PDGFα receptors [28,55]. Provocation of cell cycle progression 
is one of critical functions of PDGF receptors through Src. Entry into S phase from G phase is 
part of this process. In addition, Src plays a major role in DNA synthesis that is induced by 
PDGF receptors [69]. Furthermore, Src has a negative regulatory effect on PDGF receptors-
induced motility responses [57]  
1.3.1.2.3 PI3-kinase pathway 
Phosphoinositide 3-kinases (PI3-kinases) consist of group of lipid kinases that have the ability to 
phosphorylate the inositol ring of phosphatidylinositol (PtdIns or PI) at their 3-OH position and 
produce various 3-phosphorylated phosphoinositide such as PI3P, PI(3,4)P2, PI(3,5)P2, and 
PI(3,4,5)P3, which in turn recruit specific signaling proteins containing phosphoinositide-binding 
domains to the cellular membrane [Figure ‎1.5]. PI3-kinases have two subunits: catalytic and 
regulatory. PI3-kinases are divided to three classes based on their structure, regulation, and lipid-
binding specificity [70]. Class IA (which is downstream signaling pathway for RTKs) consists of 
p110 as a catalytic subunit and the p85 as a regulatory subunit. Phosphorylated Tyr740 and 
Tyr751 are the docking sites on the PDGFβ receptor for p85 subunit of PI3-kinase [56] and this 
binding leads to activation of the catalytic subunit. In addition to RTKs, other molecules such as 
Src tyrosine kinases, focal adhesion kinase (FAK), Ras, Rho, and Cdc42 can bind to class IA PI3-
kinase to promote its activation. PI3-kinase downstream effectors include protein kinase B 
(PKB), also called Akt. Activation of the Akt/PKB by PI3-kinase results in the translocation of 
Akt to the plasma membrane. Akt also is activated by the 3-phosphoinositide-dependent kinase 1 
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(PDK1), which is also activated by PI3-kinase. Akt activation protects cells from apoptosis and 
promotes cell survival [71]. Others downstream effectors that are activated by PI3-kinase include 
the small GTPases of the Rho family, Bruton‟s tyrosine kinase (Btk)  members of protein kinase 
C (PKC) family (PKCδ ε δ)  PLCγ  c-Jun and N-terminal kinase (JNK), and p70S6 kinase 
[28,72]. 
 
PI3-kinase pathways may have oncogenic effects in various tumors, and the overexpression of 
Akt pathway is observed in some types of cancers [73]. Akt activation leads to phosphorylation 
of BAD (Bcl2 family member), and suppression of apoptosis, which is a key phenotype of 
several malignancies. The lack of the tumor suppressor protein (PTEN) that has lipid 
phosphatase activity and can dephosphorylate PI3-kinase phospholipid products has also been 
shown in many human malignancies [73]. PDGF receptors can promote cell growth and motility 
via PI3-kinase pathway [74]. There are two different chemotactic waves of PI3-kinase activation 
by PDGF, early (5-30 minutes) and late (3-7 hours). The early wave is needed for membrane 
ruffling and chemotaxis, and the late wave of PI3-kinase activity is required for cell-cycle 
progression via PDGF-dependent DNA synthesis [74]. 
1.3.1.2.4 PLC pathway 
The phospholipase C (PLC) pathway is stimulated by various extracellular signals. Activated-
PLC enzymes hydrolyze cell membrane phospholipids PIP2 (phosphatidylinositol-4,5-
bisphosphate) to generate two second messengers: diacylglycerol (DAG) and inositol-1,4,5-
trisphosphate (IP3). DAG acts to stimulate the protein kinase C family (PKC). IP3 stimulates the 
intracellular Ca
+2
 release by binding to the IP3 receptors on intracellular Ca
+2
 storage sites of the 
cells such as the endoplasmic reticulum (ER). This intracellular process results in the release of 
Ca
+2
 stored within the ER and activation of calcium-dependent proteins. Released Ca
+2
 and DAG 
cooperate to stimulate protein kinase C (PKC) enzymes associated with the plasma membrane 
[75] [Figure ‎1.5]. Further phosphorylation of IP3 produces inositol 1,3,4,5-tetrakisphosphate; IP4 
is a regulatory kinase which regulates IP3 metabolism, compete with IP3 to bind PH domain of 
target proteins, and restores intracellular Ca
+2
 back into its storage sites. IP5 forms are involved 
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in the modulation of cell differentiation and calcium hemostasis [76]. DAG can be converted to 
phosphotidic acid, which also has its own biological functions.  
 
PLC isoforms in mammals are divided to three different groups: PLCβ  PLCγ  and PLCδ. All of 
them have X and Y regions that consist of the catalytic domain and the PH region in the N-
terminus. PLCγ isoforms have one SH3 domain  two SH2 domains  and an additional PH 
domain. PLCγ also has a calcium/lipid-binding domain (CalB) that interacts with Ca+2 and 
phospholipids. RTKs and other tyrosine kinase-dependent signaling receptors, non-receptor 
protein tyrosine kinases (PTKs), such as B cell antigen receptor (BCR) and T cell antigen 
receptor (TCR) can activate PLCγ isoforms via their SH2 domains [77,78]. PLCγ binds to 
phosphorylated tyrosine residues of activated RTKs by its SH2 domains. The phosphorylated 
PLCγ1 detaches from the receptor tyrosine kinase, and translocates to the cell membrane [79]. 
Translocation of PLCγ1 is dependent on phosphatidylinositol-3,4,5-trisphosphate that is 
produced by PI3-kinase, and binds the PH domain of PLCγ1[80]. 
 
Figure  1.5 PLCγ1/PKC‎and‎PI3-kinase pathways 
 
740 
751 
1009 
1021 
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PLCγ1 regulates various cellular functions including mitogenesis  differentiation  chemotaxis, 
and transformation. The deletion of PLCγ1 in mice results in a lethal phenotype due to global 
growth inhibition of all organs of the embryo [81]. Both PLCγ and PI3-kinase pathways 
stimulate chemotaxis and mitogenicity in response to PDGF-BB. Each of these pathways can 
compensate for the other‟s absence to promote the effect of PDGF-BB on cell chemotaxis and 
mitogenicity [81,82,83]. In addition  PLCγ and PI3-kinase both activate the Na+/H+ exchanger 
via Ca
+2
/PKC pathway after activation of PDGFβ receptors [28,84]. 
1.3.1.2.5 Protein tyrosine phosphatase  
Protein tyrosine phosphatases (PTPs), which dephosphorylate phosphotyrosines, often oppose 
the activity of tyrosine kinases. Equilibria between phosphorylation and dephosphorylation of 
tyrosine residues is an essential regulating mechanism for various downstream cascades of 
RTKs. SHP-2 and low molecular weight phosphatase are two PTPs that are identified for 
regulating PDGF receptors. SHP-2, also known as PTP1D, PTP2C, SH-PTP2, SH-PTP3 or Syp, 
is a protein tyrosine phosphatase (PTP) that contains two SH2 domains. Tyr1009 can bind to 
SH2 domains of SHP-2 and this results in both positive and negative functions downstream of 
PDGFβ receptors [85]. Phosphatase activity of SHP-2 can dephosphorylate the 
autophosphorylated tyrosines of the PDGFβ receptors as well as their substrates [28]. For 
example, SHP-2 can dephosphorylate phospho-Tyr740, a PI3-kinase binding site, phospho-
Tyr751, a Nck and PI3-kinase binding site, and phospho-Tyr771, a GTPase-activating protein 
(GAP) binding site, whereas phospho-Tyr1009 and phospho-Tyr1021 are not putative substrates 
for the phosphatase activity of SHP-2 (86). After binding to Tyr1009, SHP-2 can 
dephosphorylate and bind to Grb2, which leads to Ras activation. In addition, SHP-2 can 
stimulate the MAPK pathway independent of Ras, probably via Src activation [28,58,59]. 
Therefore, SHP-2 has both inhibitory regulatory effects with respect to PDGFβ receptor 
signaling.  
 
The low molecular weight protein tyrosine phosphatase (LMW-PTP) is another phosphatase that 
regulates PDGF receptor activation. It decreases PDGFβ receptor tyrosine phosphorylation and 
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reduces the mitogenic effects of PDGF-BB by regulating the Src and STAT pathways, which 
results in modification in the G1 cell cycle phase progression via changing in c-fos and c-myc 
expression [87].   
 
 
Figure  1.6 Cross-talk‎between‎PDGFβ‎receptors pathways 
Each of signaling pathways of PDGF receptors is not an isolated linear pathway, whereas there is an association 
among all the PDGF receptors pathways. The combination of these pathways results in cell proliferation, 
differentiation, motility, and survival [1]. 
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1.3.1.3 Cellular functions of PDGF and PDGF receptors 
PDGFs are dimers of polypeptide chains that are linked by disulfide bonds and belong to the 
mitogen family. They have multi-faceted regulatory functions and play crucial roles in cell 
growth, differentiation, proliferation, and migration during embryonic development as well as in 
adult cellular homeostasis. PDGF-AB makes up approximately 70% of the PDGF produced in 
platelets and the remaining consist of PDGF-BB; with trace amounts of PDGF-AA [88] 
[Table  1.3].  
1.3.1.3.1 Proliferation and differentiation 
When activated  both PDGFα and PDGFβ receptors induce cell proliferation with measurable cell 
division observed as early as 8-16 hours after treatment. Cell type variations and variability in expression 
levels of the receptors make it difficult to determine which of the α or β receptors has a greater association 
with the promotion of mitogenesis [89]. Compared to homodimers, heterodimeric PDGFαβ receptors 
have been shown to induce the most efficient mitogenic response [90]. The Ras/MAPK pathway is one of 
the important pathways for PDGF-induced mitogenicity [91]. The adaptor protein Nck, PI3-kinase  PLCγ  
c-Src, and sphinogosine1-1 phosphate are important Ras/MAPK-independent pathways for PDGF-
induced mitogenesis [92-94]. The mitogenic characteristics of Ras/MAPK-independent pathways depend 
on the cell type. Overactivation of various components of these pathways may result in transformation. 
PDGF receptors have several negative regulatory control mechanisms that prevent excessive cell growth, 
which could lead to malignancy. The GTPase activating protein of Ras (RasGAP), the Cbl proto-
oncogene, the low molecular weight protein tyrosine phosphatase (LMW-PTP), the SH2 domain 
containing tyrosine phosphatase SHP-2, and integrins are some of the negative regulators for the 
mitogenic responses to PDGF receptor activation [95,96]. The adaptor protein Nck has a key role in 
mitogenic signaling downstream of PDGFβ receptors after binding to phosphorylated Tyr751. 
Nck is involved in JNK serine/threonine kinase activation. In contrast to PDGFβ receptor 
mitogenic effects, several pathways downstream of PDGFβ receptors have been found to play key roles in 
differentiation of neuronal cell line PC12. Activation of MAPK  PLCγ/PKC  and Src are important for 
differentiation effect of PDGFβ receptors depending on the cell type [28]. PLCγ is important for full 
mitogenic responses of PDGF receptors in some cells such as vascular smooth muscle cells [82]. 
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In conclusion, proliferation and differentiation responses of PDGFβ receptors are regulated via 
various cellular transduction pathways. 
1.3.1.3.2 Motility 
PDGF and PDGF receptors have an important role in cytoskeletal rearrangements and migration. 
Rearrangement of the actin cytoskeleton via loss of stress fibers, the appearance of edge ruffles, 
and in some cases the formation of circular membrane ruffles, leads to cell movement [89]. Cells 
that express PDGFβ receptors are able to migrate chemotactically toward higher concentration 
gradients of PDGF-BB [97]. However  PDGFα receptor-expressing cells do not have this ability 
[89]. PDGF receptors induce two different types of cell movements: directed migration 
(chemotaxis) and random migration (chemokinesis) [43]. Chemotaxis is important for embryonic 
development and wound healing. The physiological role of chemokinesis remains unknown. PI3-
kinase is involved in cell motility [98] and mutation of Tyr740 and Tyr751 impairs chemotactic 
response of PDGFβ receptors to PDGF and the formation of edge ruffles is extinguished; 
however it does not have any effect on chemokinesis [56,99]. In addition  PLCγ1/PKC  and 
SHP-2 are important for chemotaxis whereas Ras inhibits chemotaxic response of cells to PDGF 
[97]. Other downstream pathways of PDGFβ receptors can also regulate motility response. In the 
CHO cell line  mutation of Tyr1021 (the binding site of PDGFβ receptors for PLCγ1) results in 
impairment of chemotaxis after PDGF-BB treatment [98]. However, in the same cell line, 
mutation of Tyr771 (the binding site for RasGAP) results in an elevation in migratory responses 
[98]. Interestingly, in the porcine aortic endothelial (PAE) cells, similar mutations did not affect 
cell migratory responses toward PDGF-BB [43,56]. Thus, it seems that the cell type is crucial 
with respect to migratory response related to downstream pathways of PDGFβ receptors. 
Regulating chemotactic capacity of the cell in response to PDGFβ receptor stimulation seems to 
be important in the treatment of various malignancies and cancers. In particular, PI3-kinase‟s 
proliferative and migratory effects could depend on the type of catalytic p110 subunit expressed 
or differences in downstream effectors [43]. 
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1.3.1.3.3 Survival 
PDGF plays a pivotal role in preventing cells from apoptosis, also called programmed cell death. 
The anti-apoptotic effects of PDGF and PDGF receptors in PC12 cells were dependent on the 
PI3-kinase pathway after Tyr740 and Tyr751phosphorylation. In fibroblasts and neuronal cells, 
Akt, activated downstream of PI3-kinase, showed significant anti-apoptotic effects [100]. The 
PI3-kinase/Akt pathway is a proto-oncoprotein with the ability to inhibit apoptosis; activated Akt 
phosphorylates BAD, a member of BCL-2 family, resulting in the suppression of apoptosis 
(dephosphorylated BAD has the ability to bind to BCLXL and to promote apoptosis) [28]. 
Interestingly, Ras has multiple effects on apoptosis depending on how it is activated. Ras has 
anti-apoptotic effects through activation of PI3-kinase and has pro-apoptotic effects through 
stimulation of Raf/MAPK/ERK1,2 pathway [30]. 
1.3.1.3.4 Gene regulation and expression 
PDGF receptors play a key role in gene regulation. Early growth response genes are expressed 
after PDGF receptor stimulation. Transcriptional factors fos, myc, JE, and KC are examples of 
these genes with the latter two encoding monocyte and neutrophil chemoattractants, respectively 
[43]. STATs seem to be at least partially responsible for PDGF receptor-induced transcriptional 
responses.  Stimulation of PDGFβ receptors by PDGF-BB results in a transient upregulation of 
both mRNA transcripts and protein levels of PDGFα and PDGFβ receptors [101].  
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Table  1.3 Summarized‎cellular‎effects‎of‎PDGF‎and‎PDGFβ‎receptors 
Cellular effect of 
PDGFβ‎receptor 
Effect, Downstream pathways, 
Intermediate effectors or adaptor proteins 
Tyrosine 
Phosphorylation sites 
Proliferation 
Ras/MAPK pathway 
Direct activation of 
Grb2-Sos 
 Tyr716/Tyr775 
Indirect activation of 
Grb2-Sos 
Shc Tyr579/Tyr740/ Tyr751/Tyr771 
SHP-2 Tyr763/Tyr1009 
Ras/MAPK-
independent 
pathway 
Src  Tyr579/Tyr581 
PLCγ  Tyr1009/ Tyr1021 
PI3-kinase  Tyr740/Tyr751 
Nck  Tyr751 
Differentiation 
 Ras/MAPK   Tyr716/Tyr775 
 PLCγ/PKC  Tyr1009/ Tyr1021 
 Src  Tyr579/Tyr581 
Motility and Cell 
Migration 
Chemotaxis 
PI3-kinase 
PLCγ/PKC 
 SHP-2 
+ 
Tyr740/Tyr751 
Tyr1009/ Tyr1021 
Tyr763/Tyr1009 
RasGAP 
Src/ PLCγ 
- 
Tyr771 
Tyr934 
Chemokinesis N/A  N/A 
Survival 
Anti-apoptotic 
PI3-kinase/Akt/PKB 
PI3-kinase/Ras 
+ 
Tyr740/Tyr751 
N/A 
Apoptosis Ras/MAPK - Tyr716/Tyr775 
Neuronal protection 
PLC/NMDAR 
Current 
 1021/1009 
 
1.3.1.4 Physiological role of PDGF and PDGF receptors 
1.3.1.4.1 Embryonic development 
PDGF receptors have key roles in the development of neural crest cells (NCCs). Both PDGFα 
receptors and PDGFβ receptors have complementary roles during cardiac NCCs development. 
PDGFα receptors are also important in non-neuronal and PDGFβ receptors are important in 
neuronal cardiac NCCs development [102]. PDGF-A and PDGFα receptors play key roles in 
proliferation and migration of several other organs during embryonic development including 
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lung, intestine, skin, testis, kidney, eye, CNS, axial skeleton, and teeth [36]. PDGF-B and 
PDGFβ receptors are important in cardiovascular system  kidney  CNS (particularly the cerebral 
microcirculation and BBB development), and hematopoietic development [36,204]. 
1.3.1.4.2 Neuroprotection, neurogenesis, and synaptogenesis 
Since the 1960s, our view of neurogenesis has changed dramatically [103]. Previously, it was 
thought that neuronal production and proliferation ended when development was completed 
[104]. However, recent studies have demonstrated that the neuronal stem cells (NSCs) in the 
subventricular zone (SVZ) or dentate gyrus subgranular zone (DG-SGZ) are responsible for 
maintenance and regeneration of the nervous system [32,104]. This finding has become the focus 
of intense research in neurodegenerative disease, neurological disorders, and neuronal injury.  
 
It is now accepted that not only can neurons regenerate in the adult brain, but that brain injury 
can induce neurogenesis. Brain regions in patients with epilepsy  ischemic stroke  Alzheimer‟s  
Huntington‟s  and Parkinson‟s disease all show an increase in neurogenesis [32]. The importance 
of neurogenesis and synaptogenesis in the pathophysiology and treatment of neurological 
disorders and neurodegenerative diseases such as Alzheimer‟s and Parkinson's disease highlights 
the potential for new therapies to target these processes. In early neurodegenerative diseases and 
in psychiatric disorders, both neurogenesis and synaptogenesis may be significantly impaired, 
possibly due to a reduction or dysfunction in neurotrophic factors and their receptors. Strategies 
aimed at increasing neurogenesis may be useful to several CNS disorders. 
 
The term “neurotrophic factor” is often limited to nerve growth factor (NGF)  brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4): endogenous 
soluble proteins that modulate growth, proliferation, differentiation, survival, repair, 
neurogenesis, synaptogenesis, and synaptic plasticity in neurons [105]. They exert their function 
through two distinct classes of neurotrophin receptors: p75 neurotrophin receptor (p75
NTR
), 
which belongs to the tumor necrosis factor (TNF) receptor superfamily and is a transmembrane 
glycoprotein receptor; and tropomyosin related kinase receptors (TrkA, B, and C) [106,107]. 
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Although the PDGF system is generally thought to function primarily in the periphery, its 
signaling may also have a significant effect on neuronal activity [48]. PDGF-BB has 
neurotrophic effects on neurogenesis, neuronal growth and differentiation, survival, 
synaptogenesis, and synaptic modulation. Importantly, PDGF is neuroprotective against several 
neurotoxic insults such as ischemia, infection, and various toxins [108,109]. Administration of 
other growth factors, EGF and FGF, to aged rat brain (in vivo) resulted in a 5-fold increase in 
neurogenesis compared to control, demonstrating the ability of aged brain to response to 
exogenous growth factor in order to replace neurons which are damaged or lost [110].  
 
PDGF signaling pathways may also regulate specific ion channels in neurons. Glutamate, the 
major excitatory neurotransmitter in the CNS, exerts its action via N-methyl-D-aspartate 
(NMDA) receptors  α-amino-3-hydroxy-5-methylisoxzole-4-proprionic acid (AMPA) receptors, 
and kainate receptors [111,112]. NMDA receptors have a major role in excitatory synaptic 
transmission, neuronal development, neuronal physiology, long term potentiation (LTP), and 
neuronal plasticity [112,113]. On the other hand, dysregulation in NMDA receptor activity is 
associated with neurological diseases such as disorders due to acute excitotoxic insults (e.g. 
traumatic brain injury and ischemic brain stroke) as well as diseases associated with chronic 
neurodegeneration such as Parkinson‟s  Alzheimer‟s  and Huntington‟s  prion disorders, and 
diseases resulting  from hyperexcitability or sensitization of neurons such as neuropathic pain 
and seizure disorders [112,111]. In contrast, neurodevelopmental and neuropsychiatric disorders 
such as schizophrenia and autism are associated with hypoactivity of NMDA receptors 
[112,111]. Thus, NMDA receptors have a paradox in their function; they can both have a 
neuronal protective effects and neuronal toxicity effects. Excessive NMDA receptor activity due 
to the high concentration of the glutamate results in neurotoxicity, yet learning and memory in 
hippocampus are dependent on LTP at CA1 synapses; CA1-LTP is dependent on influx of Ca
+2 
through NMDA receptors [114]. Activation of NMDA receptors in the rat dentate gyrus 
decreases neurogenesis, whereas acute treatment of rat dentate gyrus by antagonists of NMDA 
receptors results in an increase in overall density of neurons [115].  
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PDGFβ receptor activation has a long lasting inhibitory effects on NMDA currents CA1 
pyramidal hippocampal neurons which is relevant to the overactivation of NMDA receptors that 
leading to neurotoxicity [116,114]. PDGF-BB pretreatment of PDGF also regulates                     
γ-aminobutyric acid (GABAA) receptors, which have inhibitory effects on synaptic transmission 
in the CNS and are the major inhibitory ion-channel receptors in the CNS. In CA1 pyramidal 
hippocampal neurons, PDGF-BB and PDGFβ receptors cause a long lasting inhibition of NMDA 
receptor-dependent excitatory postsynaptic currents (EPSCs) and GABAA-dependent inhibitory 
postsynaptic currents (IPSCs) [49,116,117]. Both the inhibition of NMDA and GABAA receptor 
currents are dependent on Tyr1021 phosphorylation and the activation of PLCγ. EGF and BDNF 
receptors, in contrast to PDGF receptors, cause a long lasting stimulation on excitatory synaptic 
transmission [114].  
1.3.1.4.3 Wound healing  
Wound healing is a complex orchestrated cascade that tissues use to repair themselves after 
injury. Various processes including platelet aggregation, inflammation, cell proliferation, cell 
migration, and extracellular matrix production are involved. PDGF-BB and PDGFβ receptors are 
one of the growth factor systems that are involved in regulation of wound healing [36,118]. 
Platelets release PDGF-BB in the blood clot after the injury. PDGF attracts neutrophils and 
macrophage to the site of injury; PDGF-BB also attracts fibroblast and stimulates fibroblast and 
smooth muscle cell proliferation. In addition, PDGF stimulates macrophages to release fibroblast 
growth factors resulting in production of extracellular matrix scaffolds. Furthermore, PDGF has 
a role in wound contraction. In normal tissue the expression of PDGFβ receptors is low  whereas 
the expression of PDGFβ receptors is upregulated in damaged tissues, highlighting the function 
of PDGF and PDGF receptors in the wound healing process. Recombinant PDGF-BB has 
therapeutic effects on decubitus ulcers and increases the wound healing process in diabetic 
patients [36].  
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1.3.1.4.4 PDGF and PDGF receptors in diseases  
Despite numerous roles identified for the PDGF system during development, much less is known 
about the physiological function of PDGF signaling in developed animals, particularly in 
neurons. Overexpression/hyperactivity of PDGF ligands can lead to several pathological 
conditions and diseases and PDGF inhibitors have been used as a choice for cancer therapy 
[36,44]. In general, the diseases that PDGF and PDGF receptors are involved into could be 
separated to five categories: malignancies, vascular disorders, fibrosis, inflammation, and 
polymorphisms. 
 
Malignancies 
V-sis gene, simian sarcoma virus (SSV) oncogene, has been found to have a close homology 
with human PDGF-B gene [44,120]. Subsequent studies revealed that PDGF-B (c-sis) is a proto-
oncogene [121]. Many tumor cell lines express and secrete PDGF-A [122]. Further studies have 
demonstrated that autocrine/paracrine secretion of PDGF stimulates a malignant brain tumor of 
glial cell origin called glioma via PDGFα receptors  whereas PDGF-B autocrine loops stimulates 
the vasculature via PDGFβ receptors [44,123]. PDGF and PDGF receptors are expressed mostly 
in glioblastomas; however, robust expression of PDGF and PDGF receptors has been found in 
other malignant tumors as well [36]. Autocrine activation of PDGF receptors is important in the 
genesis of gliomas and sarcomas, whereas paracrine activation of PDGF receptors is seen in 
many other types of tumors including mammary, colorectal, and lung carcinoma. Both autocrine 
and paracrine PDGF activation increase tumor cell growth and stroma activity including 
accelerating VEGF expression and angiogenesis [34]. Truncated PDGFβ receptors (i.e. dummy 
receptors), receptor antibodies, kinase inhibitors, dominant negative ligands, aptamers, or 
antibodies against ligands have all been investigated for use in cancer therapy to counteract the 
overexpression and overactivation of the receptors and their cognate ligands [44].  
 
Vascular disorders 
PDGF-B and PDGFβ receptors promote the migration and proliferation of smooth muscle cells 
leading to intimal thickening and atherosclerosis. In contrast, PDGF-A and PDGFα receptors 
  30 
inhibit this migration and regulate the smooth muscle cell activity in the arterial wall [124,125]. 
Upregulated gene expression and production of PDGFs and PDGF receptors result in pulmonary 
artery vascular smooth muscle cell (vSMC) hyperplasia, a hallmark of pulmonary arterial 
hypertension (PAH) [36]. Overexpression of PDGF-B and PDGFβ receptors have roles in 
ischemic retinopathies including proliferative vitreoretinopathy, choroidal neovascularization, 
and proliferative diabetic retinopathy [36]. 
 
Fibrosis 
Overactivation/overexpression of PDGFα/PDGFβ/PDGFαβ receptors have been found in several 
fibrosis such as myelofibrosis (bone marrow fibrosis), liver fibrosis, dermal fibrosis 
(scleroderma), renal fibrosis, cardiac fibrosis, and pulmonary fibrosis [36,126-129]. 
 
Inflammation 
Robust expression of PDGF-B and PDGFβ receptors is observed in inflamed joints in patients 
with rheumatoid arthritis [36,130]. In addition, glomerulonephritis and glomerulosclerosis that 
are inflammatory kidney disorders are associated with over expression of PDGF-B and PDGFβ 
receptors resulting in massive mesangial cell proliferation and glomerular filtering destruction. In 
both of these inflammatory disorders autocrine and paracrine PDGF-B secretion and PDGFβ 
receptors over activation are responsible for the malfunction [36,131].  
 
Polymorphisms 
Single nucleotide polymorphisms in PDGF and PDGF receptor genes have been reported. 
Overexpression of PDGF-A and overactivation of PDGFα receptors are associated with neural 
tube defects and gene polymorphism. Spina bifida, anencephaly, and childhood asthma are 
related to PDGFα receptor promoter polymorphism [36]. 
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1.4 Transactivation  
Although GPCRs and RTKs were assumed to have entirely separate signaling cascades and 
functions, in the past decades it has come to light that there are several intricate interactions 
between these two receptor families. RTKs can be activated directly by their ligands or can be 
transactivated through intracellular signaling cascades via cross-talk with other receptors such as 
GPCRs; this process was first described by Daub, H. et al. 1996 and coined the term 
transactivation [132]. Transactivation pathways may contribute to the proliferative activity of 
many GPCRs. In other words, transactivation is cross-talk between two heterologous receptors in 
which the activation of the second receptor is a consequence of the primary activation of the first 
receptor. Classically, GPCRs are the initiating receptor, and RTKs are the second receptor [133]. 
Two different models have been described for RTK transactivation by GPCRs. The first model is 
the ligand-dependent model: upon activation of a GPCR, an intracellular signaling cascade is 
initiated that ultimately results in the extracellular release of the endogenous RTK ligand by 
cleavage and shedding of membrane-associated precursors via metalloproteinases of the ADAM 
family [7] [Figure  1.7]. Metalloproteinases belonging to the ADAM family such as membrane-
bound matrix metalloproteinases (MMPs) cleave and shed RTK ligands that in turn stimulate 
their cognate receptors [134]. Subsequently, receptor activation proceeds in a manner similar to 
normally-activated receptor [135]. The most well-known example of this transactivation model is 
the transactivation of epithelial growth factor (EGF) receptors [136]. For example, the 
gonadotropin-releasing hormone (GnRH) receptor transactivates EGFR through a heparin-
binding EGF-like growth factor (HB-EGF) mechanism [137]. Triple-membrane-passing-
signaling (TMPS) is a new term for this kind of transactivation; since ligand-dependent 
transactivation consists of three transmembrane signaling events including GPCR activation 
(extra to intracellular); subsequent membrane metalloproteinase activation (intra to 
extracellular); followed by activation of RTKs (extra to intracellular). An important implication 
of this type of transactivation is that nearby cells may be exposed to the released RTK ligand. In 
the other word, the released growth factors can either activate the cognate receptors on the same 
cells or on the adjacent cells. 
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Figure  1.7 Triple-membrane-passing-signaling (TMPS) transactivation 
 
The other type of transactivation is ligand-independent. In this form of transactivation, the 
activation of the receptor is entirely intracellular and independent of ligand. Thus, the 
transactivation of RTKs by GPCRs is limited to the cells that express both receptors [138] 
[Figure  1.8]. For example, dopamine D2 receptor activation results in the transactivation of 
PDGFβ receptor even in the absence of the PDGF ligand, i.e., it involves only intracellular 
signaling pathways [24,42]. Pituitary adenylyl cyclase-activating polypeptide (PACAP) 
transactivates TrkA neurotrophin receptors in a similar, ligand-independent manner [139].  
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Figure  1.8 Ligand-independent transactivation 
 
1.5 Rationale  
In the past two decades, elucidating pathways for different types of cross-communication 
between receptors has become an area of intense research. Proliferation and differentiation are 
important in many physiological and pathophysiological processes including cancer. In the brain, 
neurogenesis and synaptogenesis are keys to our understanding and treatment of 
neurodegenerative and psychiatric disorders. Although different studies on various cells have 
shown that GPCRs are able to transactivate PDGFβ receptors  the importance of this 
phenomenon remains unclear. The main questions are: Why do cells in the body require 
transactivation at all since PDGFβ receptors can be activated directly by their ligands? Why do 
cells have two similar  if not identical  pathways to regulate and activate PDGFβ receptors? What 
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is the relevance of PDGFβ receptors transactivation by GPCRs in disease? Can GPCR ligands 
substitute for RTK ligands to achieve similar downstream effects such as neuroprotection? 
 
Before we even begin understanding the physiological relevance of GPCR-induced RTK 
transactivation, we need a better understanding of the differences and/or similarities between 
direct RTK activation by ligand versus GPCR-induced transactivation of RTKs. These crucial 
findings will provide direction to future experiments on transactivation pathways in several 
model systems and the potential physiological, pathological, and therapeutic implications for 
these pathways. In this project we considered whether transactivation results in the activation of 
the same downstream cascades as direct ligand activation and whether transactivation activates 
the PDGFβ receptor to the same degree as direct activation. 
1.6 Objectives  
A complete understanding of transactivation between GPCRs and RTKs reveals a novel way for 
regulating cell signaling in both diseased and healthy systems. Many researchers have proposed 
that the proliferative and pro-survival effects of GPCRs are associated with transactivation of 
RTKs. This means that many outcomes of GPCR signaling depend on the transactivation. Since 
this phenomena is intricate and vague, current studies are focused on clarifying the downstream 
mechanism involved in transactivation. The first null hypothesis stated is that the 
phosphorylation profile of ligand-activated versus transactivated PDGFβ receptors will be 
identical. The second null hypothesis is that no differences between downstream cascades of 
PDGFβ receptors after direct activation and transactivation will be observed. Addressing these 
two hypotheses may help for future understanding of signaling differences between GPCR-
induced growth factor receptor transactivation and direct ligand activation; and, physiological 
relevance of GPCR-induced RTK transactivation. 
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‎ Chapter 2
Materials and Methods 
2.1 Materials 
Summarized table of components and antibodies were used for this project represented in 
Table  2.1 and Table  2.2. 
Table  2.1 Materials 
Components Source 
Acrylamide 30% (37.5:1) Fisher Bio Reagents 
Bicinchoninic acid (BCA) protein assay kit Thermo  
Beta-glycerophosphate MP Bio 
β-mercaptoethanol Fisher Bio Reagents 
Bromophenol blue Sigma  
Bovine serum albumin (BSA) Fisher Bio Reagents 
Butanol (1-butanol) 99% Fisher Bio Reagents 
Cell culture media (DMEM and Ham‟s F12 in a 1:1 ratio) Fisher #SH20361 
Chemiluminescent Substrate Millipore 
Dithiothreitol (DTT) Fisher Bio Reagents  
Dopamine (3,4-dihydroxyphenethylamine hydrochloride)/ Dopamine receptor agonist Sigma  
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Ethylene diamine tetraacetic acid (EDTA) Fisher Bio Reagents  
Ethylene glycol-bis (2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA) Sigma  
Ethyl alcohol 95% Fisher Bio Reagents 
Fetal bovine serum (FBS), sterile  Fisher Bio Reagents 
Glycerol 99.5% Sigma  
Glycine MP Biio 
Halt protease inhibitor cocktail, EDTA free Fisher Bio Reagents 
Hydrochloric acid 6N Fisher Bio Reagents 
Ladder (EZ-RunTM) pre-stained rec protein ladder Fisher Bio Reagents 
Methanol Fisher Bio Reagents 
Nitrocellulose membrane Fisher Bio Reagents 
Non-fat dry milk Fisher Bio Reagents 
Phosphate buffered saline (PBS) Sigma  
PDGF-BB 50ug/mL/PDGFβ receptor agonist Sigma  
100 U/mL penicillin  and 100 μg/mL streptomycin Hyclone 
(−)-Quinpirole hydrochloride ≥98% (HPLC)  solid/ Dopamine D2/3 agonist Sigma ALDRISH 
S(−)-Raclopride (+)-tartrate salt >97%, solid/ Dopamine D2/3 antagonist Sigma ALDRISH 
Sodium dodecyl sulfate (SDS) Fisher Bio Reagents 
Serotonin (5-HT; 5-hydroxytryptamine hydrochloride)/ Serotonin receptor agonist Cedarlane  
Sodium chloride Sigma 
Sodium orthovanadate (Na3VO4) MP Bio 
Sodium pyrophosphate,99% Acros 
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Components Source 
Tetramethylethylenediamine (TEMED) BIO-RAD 
Tris Base Fisher Bio Reagents 
Triton-X100 MP Bio 
Trypsin 0.25% Sigma 
Tween 20 Fisher Bio Reagents 
8-hydroxy-DPAT(8-hydroxy-2-dipropylaminotetralin hydrobromide)/ 
5HT1A/5HT7 agonist 
Cedarlane  
 
Table  2.2 Antibodies 
Antibodies against Dilution Source  
β-actin 1:800 Mouse Santa Cruz 
PDGFβ receptor 1:800 Rabbit Santa Cruz 
PDGFβ receptor phosphorylation 1021 1:500 Rabbit Santa Cruz & Cell Signaling 
PDGFβ receptor phosphorylation 1009 1:500 Rabbit Cell Signaling Antibody sampler kit 
PDGFβ receptor phosphorylation 740 1:500 Rabbit Cell Signaling Antibody sampler kit 
PDGFβ receptor phosphorylation 751 1:500 Rabbit Cell Signaling Antibody sampler kit 
PDGFβ receptor phosphorylation 771 1:500 Rabbit Cell Signaling Antibody sampler kit 
ERK1/2  1:1000 Rabbit Cedarlan 
phospho-ERK1/2 1:1000 Rabbit Cedarlan 
Phosphor-Akt (Ser473) 1:1000 Rabbit Cell Signaling Antibody sampler kit 
Phosphor-Akt (Ser308) 1:1000 Rabbit Cell Signaling Antibody sampler kit 
Akt  1:1000 Rabbit Cell Signaling Antibody sampler kit 
Phospho-c-Raf (Ser259) 1:1000 Rabbit Cell Signaling Antibody sampler kit 
Phospho-GSK-3β (Ser9) 1:1000 Rabbit Cell Signaling Antibody sampler kit 
Phospho-PTEN (Ser380) 1:1000 Rabbit Cell Signaling Antibody sampler kit 
Phospho-PDK1 (Ser241) 1:1000 Rabbit Cell Signaling Antibody sampler kit 
PLCγ1 1:1000 Rabbit Cell Signaling Antibody sampler kit 
Phospho-PLCγ1(Tyr783) 1:1000 Rabbit Cell Signaling Antibody sampler kit 
PLCγ2 1:1000 Rabbit Cell Signaling Antibody sampler kit 
Phospho- PLCγ2 (Tyr1217) 1:1000 Rabbit Cell Signaling Antibody sampler kit 
Phospho- PLCγ2 (Tyr759) 1:1000 Rabbit Cell Signaling Antibody sampler kit 
Goat anti-rabbit HRP secondary antibody  1:10000 Goat-anti-rabbit Thermo 
Goat-anti mouse HRP secondary antibody 1:5000 Goat-ant-mouse Thermo 
 
2.2 Methods 
The SH-SY5Y human neuroblastoma cell line is a third subcloned cell line of SK-N-SH cells.  
The SK-N-SH cell line was established in 1970 from a bone marrow biopsy of a four-year-old 
neuroblastoma female patient with sympathetic adrenergic ganglia origin. Since 1980, SH-SY5Y 
cell line has been widely used in experimental neurological studies because it expresses many 
biochemical and functional neuronal properties such as exhibiting tyrosine and dopamine-β-
  37 
hydroxylases, the norepinephrine (and serotonin) transporter, as well as opioid, muscarinic, 
dopamine, and growth factor receptors. Therefore, the SH-SY5Y cell line is often used in 
experiments on metabolism, analysis of neuronal differentiation, neuronal function related to 
neurodegenerative disorders, neurotoxicity and neuroprotection [140]. We also have extensive 
experience in the lab with using SH-SY5Y cells for transactivation studies [141,142]. 
 
SH-SY5Y cells were obtained from Dr. Shilpa Buch (University of Nebraska Medical Centre in 
2009). Cells were cultured in a complete growth media consisting of DMEM with Ham‟s F12 in 
a 1:1 ratio supplemented with 10% fetal bovine serum (Thermo Fisher), and 1% 
penicillin/streptomycin at a temperature of 37°C, under 5% CO2 and 98% air. The media was 
changed every two-three days.  
2.2.1 Treatment, cell lysis, protein assay  
For cell treatment, quinpirole, D2-family dopamine receptor agonist; 3,4-
dihydroxyphenethylamine hydrochloride (dopamine); 5-hydroxytryptamine hydrochloride 
(serotonin); 8-OH-DPAT, a 5HT1A and 5HT7 receptor agonist; raclopride,  a dopamine D2/3 
receptor antagonist; and PDGF-BB , a ligand for PDGFβ receptors  were used. Cells were 
incubated with drugs for various time periods depending on the specific experiment. For studies 
that used a receptor antagonist, cells were pre-incubated for 5 minutes prior to agonist treatment. 
After drug treatment, cells were washed with ice-cold phosphate buffered saline (PBS) with pH 
7.4. PBS is a balanced salt solution for maintaining pH, regulating osmotic balance, and 
providing water and essential inorganic ions for short-term cell incubation. PBS was drained and 
the ice-old lysis buffer [20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 30 
mM sodium pyrophosphate, 1 mM betaglycerophosphate, 1 mM sodium orthovanadate 
(Na3VO4), 1% triton and 1% Halt protease and phosphotase inhibitor (Thermo)] [Table  2.3] was 
used in order to lyse the cells. 80 μL of lysis buffer was used for each 2 cm well. Cells were 
scraped and sheared by forcing them through 26 gauge needles for lysis. Insoluble material of the 
lysates was pelleted via centrifugation at 14000 x g for 20 minutes at 4 ˚C  and supernatants 
collected.  
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Table  2.3 Lysis buffer components  
Lysis buffer 
 
A lysis buffer breaks the cell membrane in order to release the 
cell contents and proteins. It improves protein stability and 
keeps them in the solution 
 
[20 mM Tris-HCl pH 7.5,150 mM NaCl, 1 mM EDTA,  
1 mM EGTA, 30 mM sodium pyrophosphate, 
1 mM betaglycerophosphate, 1 mM sodium orthovanadate 
(Na3VO4), 1% triton and 1% Halt Protease and phosphotase 
inhibitor (Thermo)] 
Tris-HCl Tris-Hcl regulates the acidity and osmolarity of the solution 
NaCl NaCl maintains ionic strength of medium 
EDTA 
(Ethylene diamine tetraacetic acid) 
EDTA and EGTA are preservatives and chelators for divalent 
cations; they can reduce the activity of proteolytic enzymes 
that require calcium and magnesium ions as cofactors. 
Therefore, they preserve the proteins of digestion via 
proteolytic enzymes.  EDTA inhibits the metalloproteases that 
require Mg2+ and Mn2+ 
EGTA 
(Ethylene glycol tetraacetic acid) 
EGTA, the same as EDTA, reduces oxidation damage, 
chelates metal ions, and inhibits the metalloproteases that 
require Ca2+ 
Sodium pyrophosphate 
Sodium pyrophosphate irreversibly inhibits dephosphorylation 
of proteins (Ser/Thr phosphatases inhibitor) 
Beta-glycerophosphate 
Beta-glycerophosphate irreversibly inhibits dephosphorylation 
of proteins (Ser/Thr phosphatases inhibitor) 
Sodium orthovanadate (Na3VO4) 
Na3VO4 irreversibly inhibits dephosphorylation of proteins 
(Tyr and alkaline phosphatases inhibitor) 
Triton 
Triton is a detergent, and it lyses cell membranes, solubilizes 
membrane proteins and lipids, and controls protein 
crystallization 
Halt Protease 
Halt blocks or inactivates endogenous proteolytic and 
phospholytic enzymes, which are released from cells during 
cell lysis and degrade proteins of interest and their activation 
states. Usually, it serine/threonine and tyrosine phosphatases 
and prevents protein degradation and simultaneously preserves 
phosphorylation. 
 
After lysis, the total protein concentration of samples was determined by using a bicinchoninic 
acid (BCA) protein acid kit (Thermo, Fisher). In 96-well plates, various concentrations of bovine 
serum albumin (BSA) were used by diluting BSA with Milli-Q water and the solubilization 
buffer [20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM ethylene diamine tetraacetic acid EDTA, 
1 mM EGTA, 30 mM sodium pyrophosphate, 1 mM betaglycerophosphate, 1 mM sodium 
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orthovanadate and 1% triton] [Table  2.4] for making a standard curve. For samples, 30 µL of 
Milli-Q water and 8 µL of solubilization buffer were mixed with 2 µL of each sample in 
duplicate. 300 µL of Working Reagent A:B in a 50:1 ratio (Thermo Fisher) was added to each 
well cell and incubated for 30 minutes at 37˚C. Absorbance was measured by Spectra Max M5 
Multi-Mode Micro plate Reader (Molecular Devices, Sunnyvale, CA) at 562 nm. For calculating 
the protein concentration of each sample, first, the average of blank absorbance measurement in 
standard was subtracted from the measurements of all other standards and all samples replicates. 
The standard curve was prepared by plotting the average blank-corrected data for each BSA 
standard versus its concentration in μg/mL. The standard curve was used for determining the 
protein concentration of each sample.  
 
Table  2.4 Solubilization buffer components  
 
Solubilization buffer 
A solubilization buffer breaks interactions associated with protein 
aggregation including disulfide bonds, hydrogen bonds, van der 
Waals forces, ionic interactions, and hydrophobic interactions. 
These interactions lead to protein aggregation and precipitation 
that result in artifacts or sample loss. A good solubilization is 
important for a successful electrophoretic separation process. 
 
[20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM ethylene 
diamine tetraacetic acid EDTA, 1 mM EGTA, 30 mM sodium 
pyrophosphate, 1 mM betaglycerophosphate, 1 mM sodium 
orthovanadate and 1% triton] 
Tris-HCl 
Tris-Hcl regulates the acidity and osmolarity of the solution .As 
both pH and ionic strength influence protein stability and 
solubility, choosing an appropriate buffer is important. The choice 
of buffer and pH influences the results of protein solubilization. 
NaCl NaCl maintains ionic strength of medium 
EDTA 
(Ethylene diamine tetraacetic acid) 
EDTA reduces oxidation damage, chelates metal ions, and inhibits 
the metalloproteases that require Mg2+and Mn2+ 
EGTA 
(Ethylene glycol tetraacetic acid) 
EGTA reduces oxidation damage, chelates metal ions, and inhibits 
the metalloproteases that require Ca2+ 
Sodium pyrophosphate Sodium pyrophosphate is a Ser/Thr phosphatases inhibitor 
Beta-glycerophosphate Beta-glycerophosphate is a Ser/Thr phosphatases inhibitor 
Sodium orthovanadate (Na3VO4) Na3VO4 is a Tyr and alkaline phosphatases inhibitor 
Triton 
Triton is a detergent and, it lyses cell membrane, solubilizes 
membrane proteins and lipids, and controls protein crystallization 
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2.2.2 Western blotting 
Western blotting or immunoblotting is a qualitative and semiquantitative protein analysis 
technique. It works via antibody-antigen interaction that helps to identify a target protein in the 
complex protein mixture. For our experiments, western blotting was used to separate proteins 
based on their molecular weights. Western blotting consists of three phases: electrophoresis, 
transferring, and immunoblotting. 
2.2.2.1 Polyacrylamide gel electrophoresis (PAGE) 
Polyacrylamide gel electrophoresis (PAGE) is a process for separating and identifying the 
macromolecule target such as proteins and peptides in a mixture of macromolecules solution. 
The process was based on a protein mass-charge ratio separation. We used 8% acrylamide gels, 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), containing resolving 
gel (8%) and stacking gel (4%).  
2.2.2.1.1 Preparation of SDS-PAGE gel 
SDS-PAGE gel is created via the polymerization of two compounds, acrylamide and N,N'-
methylene bisacrylamide. The polymerization of gel begins with the addition of ammonium 
persulfate (APS) and tetramethylethylenediamine (TEMED). APS induces the polymerization of 
acrylamide and bisacrylamide monomers and then decomposes to form free radicals; TEMED 
promotes the polymerization by stabilizing the free radicals and acting as an oxygen scavenger, 
since acrylamide and bisacrylamide are nonreactive by themselves. Bisacrylamide acts as a 
cross-linking agent. These components make a neutral hydrophilic gel that has a three 
dimensional structure that consists of hydrocarbons cross-linked with methylene groups. The 
pore size of the gel depends on the size of the protein of interest. Acrylamide alone forms linear 
polymers, and using bisacrylamide helps make crosslinks among polyacrylamide chains. The 
pore size of the gel is based on the total amount of acrylamide and the amount of cross-linker. 
The higher the acrylamide concentration and the higher the ratio of bisacrylamide to acrylamide, 
the lower the pore size of the gel and the lower the electrophoretic mobility. By varying the total 
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monomer concentration (which is called %T) and weight percentage of cross linker, (which is 
called %C), the pore size of the gel can be obtained based on the size of the protein of interest. 
The higher %T indicates the higher polymer-to-water ratio and the smaller pores. 
 
For casting gels, we assembled the gel glasses on the gel stand appropriately. Resolving gel (8%) 
was prepared by mixing the appropriate quantity of components of resolving gel [Resolving gel 
(8%): Milli-Q water 2.43 mL, Tris HCl 1 M (pH 8.8) 3 mL, acrylamide: bisacrylamide 30:0.8% 
w/v 2 mL, SDS 20% 38 μL, APS 10% 36 μL, TEMED 5 μL]. The resolving gel solution was 
poured in to the space between gel glasses immediately. The solution was poured within 2-3 cm 
of the top of the glasses. The top of the gel was covered by water-saturated n-butanol. After one 
hour, the resolving gel solution was prepared by mixing the components of stacking gel 
[Stacking gel (4%): Milli-Q water 3.6 mL, Tris HCl 1 M (pH 6.8) 630 μL, acrylamide: 
bisacrylamide 30:0.8% w/v 660 μL, SDS 20% 25 μL, APS 10% 25 μL  TEMED 5 μL]. The n-
butanol on the top of the resolving gel was drained and the remaining was decanted with filter 
paper. The stacking gel solution was poured on top of the resolving gel and the comb was 
inserted between two glasses. After 15-20 minutes the gel polymerization was done and the gel 
was ready for using. The comb was carefully removed and the gel was used for electrophoresis.   
2.2.2.1.2 Preparation of samples, sample loading and gel running 
After correcting the volume of the samples to account for variation in protein concentrations, 
samples were diluted in the 3× loading buffer [Table  2.5], and heated at 90-95 °C for 5 minutes. 
The 3× loading buffer means the mixture of one volume of the sample with 2 volume of the 
loading buffer [240 mM Tris-HCl at pH 6.8, 6% w/v SDS, 30% v/v glycerol, 0.02% w/v 
bromophenol blue, 50 mM dithiothreitol DTT  5% v/v β-mercaptoethanol]. After assembling the  
electrophoresis apparatus, running buffer [25 mM Tris base at pH 8.3, 0.1% w/v SDS, 190 mM 
Glycine, Milli-Q water] [Table  2.6] was poured to the electrophoresis apparatus. The running 
buffer must cover all top of the gel(s) in the electrophoresis apparatus. The samples were loaded 
to the well-cells of the gel and appropriate ladder as a molecular weight marker was used in the 
first well-cell of the gel. A total of 25-40 μg proteins per well were loaded. After loading, gel 
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was run at 60 V for 30-40 minutes until the blue dye passed the stacking gel. The voltage was 
increase after passing stacking to 100-120 V for approximately 60 minutes. 
Table  2.5 Loading buffer components  
 
Loading buffer 
Antibodies usually recognize a specific part of the protein 
called epitope. In the 3D conformation structure of the protein, 
this part can be inaccessible. To enable the access of the 
antibody to the recognition site of protein, unfolding or 
denaturing the protein is essential. A loading buffer is used for 
this purpose 
  
[240 mM Tris-HCl at pH 6.8, 6% w/v SDS, 30% v/v glycerol, 
0.02% w/v bromophenol blue, 50 mM dithiothreitol DTT, 5% 
v/v β-mercaptoethanol] 
Tris-HCl Tris-HCl works as a buffer to maintain the appropriate pH  
Sodium dodecyl sulfate (SDS) 
Dithiothreitol (DTT) 
β-mercaptoethanol 
Heating at 90-95°C 
Actual denaturation of the samples happens via SDS, DTT, and 
heat. SDS, an ionic detergent with an anionic head group and 
lipophilic tail, binds to proteins non covalently, adds negative 
charge to the amino acids, and breaks up the secondary and the 
tertiary dimensional structure of the proteins. Indeed, SDS can 
denature proteins molecules without damaging or breaking 
peptide bonds. Covalent and non-covalent linkages to other 
molecules and disulfate bonds preserve the quaternary 
structure of the proteins. To complete denaturation, heating can 
shake up the molecules and allows SDS to bind to the 
hydrophobic regions that are tightly associated with lipids. The 
covalent disulfate bonds that are related to the sulfhydryl (-SH) 
group of the amino acid cysteine, the last part of the quaternary 
structure of the proteins, will be reduced and denatured by 
DDT. β-mercaptoethanol reduces disulfide bonds as well and 
disrupts protein cross-links. At the end the process, the samples 
are left in primary structure only, and in the presence of SDS, 
the intrinsic protein charges are masked; thus, during SDS-
PAGE, the rate of protein migration is determined by their 
mass. Then, the SDS-bound proteins migrate through the gel 
from the negative charged electrode toward the positive 
charged electrode. Therefore, proteins with less molecular 
weight move quickly through the gel compared to proteins 
with higher molecular weight.  
Glycerol 
Glycerol helps the samples sink easily into the wells of the gel 
and makes the sample more dense than the sample buffer; 
therefore the samples will remain in the bottom of the wells 
rather than float. 
Bromophenol Blue 
Bromophenol blue, a tracking dye, helps determine how far the 
separation has progressed. 
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Table  2.6 Running buffer components  
Running buffer 
A running buffer helps proteins to migrate through 
electrophoresis gel  
 
[25 mM Tris base at pH 8.3, 0.1% w/v SDS, 190 mM Glycine, 
Milli-Q water] 
Tris-HCl Tris-HCl works as a buffer to maintain the appropriate pH  
Sodium dodecyl sulfate (SDS) SDS is an ionic detergent  
Glycine 
SDS-PAGE gel is composed of resolving gel that is buffered 
with Tris and adjusted to pH 8.8, and the stacking gel is 
adjusted to pH 6.8 by the Tris buffer. In addition, a running 
buffer is buffered by Tris and adjusted to pH 8.3. Glycine is a 
weak acid with the ability to be presented in two different 
states: uncharged and charged. Glycine at low pH is protonated 
and uncharged, and at higher pH is negatively charged. 
Starting to run a gel at a constant voltage is forces glycine ions 
in the running buffer to transfer from the cathode toward 
samples and the stacking gel. The stacking gel has lower pH, 
and passing the glycine through it uncharges and slows down 
the glycine. Furthermore, chloride ions available in the 
stacking gel and samples move away from the cathode as well. 
Thus, high electrical resistance happens in the stacking part of 
the gel. This electrical field forces the negatively charged 
proteins in the samples to move through the stacking gel just 
behind the chloride ions and in the tight bands. Thus, the result 
of moving the electrical zone is the migration of the protein 
from the stacking gel to the resolving gel. The migration of the 
proteins in the resolving gel depends on molecular weight. In 
the resolving gel, the pH goes up and the glycine becomes 
charged. Therefore, because of the pore and sieving 
characteristics of the resolving gel, the mobility of the glycine 
goes up and the mobility of proteins goes down. Glycine 
passes the proteins, and the proteins pass the resistance zone 
and move at their own pace. 
 
2.2.2.2 Transferring  
Wet electrophoretic transferring was used for moving the proteins from gel to the synthetic 
membrane. Immobilized proteins on the membrane then become accessible to interactions with 
antibodies. Nitrocellulose membrane (Thermo) was used for transferring. In wet transferring, the 
membrane and gel are sandwiched between sponges and filter papers, 
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(sponge/paper/gel/membrane/paper/sponge) and are kept together by a nonconducting cassette 
and submerged in the tank full of ice cold transfer buffer [3.0285 gr Tris-HCl, 14.2595 gr 
glycine, 200 mL Methanol, 800 mL Milli-Q-Water] [Table  2.7]. The membrane is placed close 
to the positive electrode and the gel is paced close to the negative electrode. After applying 
electricity, the negatively-charged proteins move toward the positively-charged electrode. The 
membrane binds with high affinity to the proteins and they stop migrating once bound. The 
transferring time was varied from 90 minutes to 3 hours depending on the primary antibody that 
was going to be used. The voltage for 90 minutes was 100 V, and for 3 hours 70 V.  
 
Table  2.7 Transferring buffer  
Transfer Buffer 
A transfer buffer is used for moving the proteins from gel 
to the synthetic membrane 
 
[3.0285 gr Tris-HCl ,14.2595 gr Glycine, 200 mL Methanol, 
800 mL Milli-Q-Water] 
Tris-Base Tris-Hcl works as a buffer to maintain the appropriate pH 
Glycine 
Glycine is a weak acid with the ability to be presented in two 
different states: uncharged and charged. Glycine at low pH is 
protonated and uncharged, and at higher pH is negatively 
charged. It pushes the protein forward onto the membrane 
through repulsive force. 
Methanol 
Methanol dissociated SDS from the sample proteins and 
increases protein absorption on to membrane 
 
2.2.2.3 Immunoblotting 
After transferring, the membranes were blocked for an hour in blocking buffer [5% non-fat milk 
in Tris-buffered saline solution with 0.1% Tween 20 (TBS-T)] [Table  2.8] at room temperature. 
Then, membranes were incubated overnight at 4°C with the primary antibody (diluted in the 
blocking buffer). Membranes were washed with TBS-T three times for 10 minutes each. Then, 
they were incubated with the secondary antibody conjugated to horse radish peroxidase (HRP) 
for one hour at room temperature. Membranes were washed again with TBS-T three times for 10 
minutes each. Finally, western chemiluminescent substrate (Millipore, Billerica, MA) was 
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applied for 5 minutes in order to visualize proteins. Images of protein bands were taken using the 
Kodak Image Station 4000 MM Pro Imaging Station. Protein bands were identified by their 
molecular weights by comparing them with a standard ladder (fisher BioReagents EZ-Run
TM
 
Pre-Stained Rec Protein Ladder). The net intensity of each protein band was assessed by Kodak 
Molecular Imaging software. The protein band intensities were normalized to the control band 
(vehicle or no treatment), and each phosphorylation band intensity after normalization to control 
was normalized to its total protein band expression intensity. β-actin served as a loading control 
for normalization. If necessary, membranes were stripped by stripping buffer (1.5% w/v glycine, 
0.1% w/v SDS, 1% v/v Tween 20 at pH 2) and additional primary antibodies were used for 
blotting. One limitation of the current work is that the primary antibodies for different 
phosphorylation sites at PDGFβ receptors might cross-react with protein tyrosine kinases or 
receptor tyrosine kinases when highly overexpressed. 
 
Table  2.8 Blotting procedure  
Blotting process [5% non-fat milk in Tris-buffered saline solution with 0.1% 
Tween 20 (TBS-T)] 
Blocking 
A nitrocellulose membrane has an affinity for proteins. To 
prevent non-specific binding of antibodies during blotting 
process, it is important to block the rest of membrane. 
Incubation (primary antibody) 
Primary antibody is an antibody that recognize the target 
protein 
Washing  
Washing is essential in order to get rid of unbound reagents 
and antibodies. It reduces background noise and increases the 
signal/noise ratio. 
Incubation (secondary antibody) 
As primary antibody is not detectable directly, the tagged 
secondary antibody, which is linked to an enzyme, is used for 
detecting the primary antibody. The choice in choosing the 
secondary antibody is based on the species that the primary 
antibody was obtained from.  
Washing 
Insufficient washing leads to high background noise and 
excessive washing results in attenuation in sensitivity due to 
the elution of the antibody or antigen 
Incubation (substrate) 
The enzyme on the secondary antibody drives a reaction 
Substrate in order to visualize proteins. 
Imaging  Kodak 4000MM Pro Imaging Station 
Stripping (1.5% w/v glycine, 0.1% w/v SDS, 1% v/v Tween 20 at pH 2)   
Washing Washing is for getting rid of unbound reagents 
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2.2.3 Statistical analysis 
Statistical analysis of the data was calculated using the Prism GraphPad program. For drawing 
graphs we used same program. Data were analyzed by one-way ANOVA, time, drug dose, and 
drug effects were variable factors. For statistical tests, significance level was set to α = 0.05.  
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 Chapter 3
Results 
 
In this chapter, the main focus is to clarify the potential differences between activation, 
phosphorylation  and downstream pathway of PDGFβ receptors after direct ligand activation 
compared to transactivation.  
3.1 Comparison‎between‎transactivation‎of‎PDGFβ‎receptors‎by‎various‎
agonists‎of‎GPCRs‎and‎direct‎activation‎of‎PDGFβ‎receptors 
To evaluate any differences between the magnitude of the change on the phosphorylation state of 
PDGFβ receptors (Tyr1021) after direct activation and transactivation, SH-SY5Y cells were 
treated with quinpirole (10 μM, Q), dopamine (100 nM, D), serotonin (100 nM, 5-HT),              
8-DPAT (10 nM, PAT), and PDGF (1 ng/mL, P) for 10 minutes. To compare the effect of 
transactivation with direct activation on downstream effectors of PDGFβ receptors  the fold 
changes on pERK1/2 were also evaluated. The results were analyzed for phospho-PDGFβ 
receptor at Tyr1021 and phospho-ERK1/2 immunoreactivity as a phosphorylation site and 
downstream effector of PDGF receptors respectively. The activation of PDGFβ receptors by       
1 ng/mL PDGF-BB increased the phosphorylation state of the receptor almost 100-fold, whereas 
application of the agonists of GPCRs were able to increase the phosphorylation states by only    
2-3 fold [Figure  3.1]. Interestingly, PDGF-BB did not increase ERK1/2 phosphorylation to a 
significantly greater extent than GPCR agonists. Application of GPCR agonists resulted in a 2-3 
fold increase in phosphorylation state of ERK1/2 compared to direct activation of PDGFβ 
receptors that showed almost 4-fold increases in phosphorylation state of ERK1/2 [Figure  3.2]. 
The dopamine D4 receptors stimulate ERK1/2 through transactivation of PDGFβ receptors [143]. 
Thus  activation of ERK1/2 via quinpirole is associated with downstream of PDGFβ receptors. 
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Figure  3.1 Comparison‎between‎transactivation‎and‎direct‎activation‎of‎PDGFβ‎receptors  
Transactivation of PDGFβ receptors via various GPCR agonists for 10 minutes showed almost same amount of 
increase in phosphorylation states of p-Y1021 that is 2-3 fold greater compared to non-treated-cells. However, direct 
activation of PDGFβ receptors showed almost 100 fold increase in phosphorylation state. The data were normalized 
to the non-treated-cells (vehicle) as a control to deduct the constitutive activity of the receptors, and then were 
normalized to total PDGFβ receptors expression. β-Actin served as a loading control. The data represent the mean ± 
standard error of the mean (S.E.M.) for five independent experiments. */V shows statistically significant result with 
p < 0.05 compared to non-treated-cells; */P shows statistically significant results with p < 0.05 compared to direct 
activation of the PDGFβ receptor with PDGF-BB. One-way ANOVA were used for statistical calculation. 
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Figure  3.2 Comparison‎between‎downstream‎effector‎of‎PDGFβ‎receptors‎activation‎after‎direct‎activation‎
and transactivation  
Despite the phosphorylation profile of ligand-activated versus transactivated PDGFβ receptor that showed a 
statistically significant difference, comparison between ERK1/2 activation for transactivation and direct activation 
did not show any significant differences in results. The data were normalized to the non-treated-cells (vehicle) as a 
control to deduct the constitutive activity of the receptors, and then were normalized to total protein ERK1/2 
expression for downstream effector as a second control. β-Actin served as a loading control. The data represent the 
mean ± standard error of the mean (S.E.M.) for five independent experiments. 
 
3.2 Time-course for quinpirole transactivation of‎the‎PDGFβ‎receptor 
To evaluate the incubation time for maximal dopamine D2 receptor transactivation of the PDGFβ 
receptor in SH-SY5Y cells, the cells were treated with quinpirole (10 μΜ)  dopamine (100 nM), 
and PDGF-BB (1 ng/mL) from 0 to 30 minutes. Cell treatment by quinpirole for 0 to 30 minutes 
represented sustained phosphorylation of the PDGFβ receptor at Tyr1021 over the time course, 
with a slight increase (but not significant) between 10 and 30 minutes; 10 minutes was picked as 
a best treatment time since our project was based on acute treatment of the cells [Figure  3.3B]. 
The time-course graph for dopamine revealed maximal phosphorylation between 15 and 30 
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minutes [Figure  3.3C] and 20 minutes for PDGF-BB [Figure  3.3A]. Application of PDGF-BB    
(1 ng/mL) to SH-SY5Y cells resulted in a rapid increase in PDGFβ receptor phosphorylation at 
Tyr1021 until minutes 20 followed by a decrease in phosphorylation. 
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Figure  3.3 A, B, C. Time course comparing transactivation‎and‎direct‎activation‎of‎PDGFβ‎receptors 
Representative graphs and blots for activation of phospho-PDGFβ receptor Tyr1021 with quinpirole  dopamine, and 
PDGF-BB are shown in Figure 3.3A, 3.3B, and 3.3C. The graph in Fig 3.3A shows the time-course for direct 
activation of PDGFβ receptor via PDGF-BB by evaluating the fold change in phospho-PDGFβ receptor at Tyr1021. 
Fig 3.3B represents the time-course for transactivation of PDGFβ receptors via quinpirole by evaluating the fold 
change in phospho-PDGFβ receptor at Tyr1021. Time-course for transactivation of PDGFβ receptors via dopamine 
by evaluating the fold change in phospho-PDGFβ receptor at Tyr1021 is shown in Fig 3.3C. The results for the time 
course were analyzed for phospho-PDGFβ receptor Tyr1021 immunoreactivity. The data were normalized to the 
non–treated-cells (vehicle) as a control and to total PDGFβ receptor expression. β-Actin served as a loading control. 
The data represent the mean ± standard deviation (S.D.) for two to nine independent experiments for quinpirole, two 
independent experiments for dopamine, and three independent experiments for PDGF-BB 1 ng/mL.   
 
3.3 Raclopride blocks transactivation‎of‎PDGFβ‎receptor‎by‎quinpirole 
The dopamine D2/3 receptor antagonist, raclopride, was used to investigate whether quinpirole 
exerts its effect via dopamine D2/3 or D4 receptors to transactivate PDGFβ receptors. SH-SY5Y 
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cells were preincubated with raclopride (500 nM) for 5 minutes; then the cells were treated by 
quinpirole (10 μM) or PDGF-BB (0.1 ng/mL) for 10 minutes [Figure  3.4]. Raclopride blocked 
quinpirole, but not PDGF-BB-induced phosphorylation. At a concentration of 500 nM, 
raclopride shows some selectivity for dopamine D2/3 receptors versus dopamine D4 receptors 
[144]. Thus, these data suggest that quinpirole is acting through dopamine D2/3 receptors to 
transactivate PDGFβ receptors in SH-SY5Y cells [Figure  3.5]. 
 
 
 
Figure  3.4 Procedure of cell treatments by raclopride 
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Figure  3.5 Raclopride‎blocks‎the‎transactivation‎of‎PDGFβ‎receptors‎via‎quinpirole  
Preincubation of the SH-SY5Y cells by raclopride for 5 min blocked dopamine D2/D3 receptors and inhibited 
transactivation of the PDGFβ receptors via quinpirole. Raclopride inhibited quinpirole-induced Tyr1021 
phosphorylation. There was no significant effect when raclopride was administered alone. The results were analyzed 
for phospho-Tyr1021 as a phosphorylation site of the PDGFβ receptors. Cells were lysed after treatment and were 
evaluated by western blotting. The data were normalized to the non-treated-cells (vehicle) as a control and to total 
PDGFβ receptors expression for phosphorylation site as a second control. β-Actin served as a loading control. The 
data represent   mean ± S.E.M. for four independent experiments. The data for transactivation and direct activation 
did not show any statistically significant results on fold change of phospho-PDGFβ receptor Tyr1021with p < 0.05. 
One-way ANOVA was used for statistical calculation. 
 
 
3.4 Dose-response curve for quinpirole transactivation 
To evaluate the effect of increasing the concentration of quinpirole on Tyr1021 phosphorylation, 
SH-SY5Y cells were treated with quinpirole (100 nM – 100 μM) for 10 minutes. As expected, 
the phosphorylation at Tyr1021 is concentration-dependent. Quinpirole increased the phospho-
PDGFβ receptor Tyr1021 state in SH-SY5Y cells with the half maximal effective concentration 
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(EC50) of 5.3 μM. In D293 cells, EC50 for quinpirole activating D2-family dopamine receptors 
was 0.57 nM [145] [Figure  3.6]. 
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Figure  3.6 Dose-response‎curve‎for‎PDGFβ‎receptor‎transactivation‎via‎quinpirole  
The dose-response curve was made by treating cells via various concentration of quinpirole from lower dose to 
higher dose and evaluating the amount of fold change in phospho-PDGFβ receptor Tyr1021  in order to find the best 
dose for treating cells. Cells were lysed after treatment and were evaluated by western blotting. The results for dose-
response were analyzed for phospho-Tyr1021 immunoreactivity. The data were normalized to the non-treated-cells 
(vehicle) as a control and to total PDGFβ receptors expression. β-Actin served as a loading control. The data 
represent the mean ± standard deviation (S.D.) for three independent experiments. 
 
 
 
EC50=5.3μM 
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3.5 Does ligand-activation versus transactivation of the PDGFβ‎receptor 
produce different tyrosine phosphorylation profiles 
To evaluate whether the phosphorylation profile of ligand-activated versus transactivated PDGFβ 
receptor is similar, SH-SY5Y cells were treated with 10 μM quinpirole  100 nM serotonin,         
1 ng/mL PDGF-BB, or 0.1 ng/mL PDGF-BB for 10 minutes. Transactivation of PDGFβ receptor 
via quinpirole resulted in statistically significant differences on phospho-Tyr1021, phospho-
Tyr771, and phospho-Tyr740 when compared to direct activation of PDGFβ receptors with         
1 ng/mL PDGF-BB (p < 0.05)[Figure  3.7A]. Direct activation of PDGFβ receptors resulted in 
statistically significant increases in the phosphorylation states of Tyr1021, Tyr771, and Tyr740 
compared to vehicle (with p < 0.05) [Figure  3.7A]. Transactivation of the PDGFβ receptor by 
quinpirole resulted in statistically significant difference on phospho-Tyr771 and phospho-Tyr751 
(p < 0.05) compared to direct activation of PDGFβ receptors by 0.1 ng/mL PDGF-BB 
[Figure  3.7B]. Similar results were observed after the application of serotonin at Tyr771 and 
Tyr740 [Figure  3.7C].   
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Figure  3.7 A,B,C. Dose ligand-activation versus transactivation‎of‎PDGFβ‎receptor‎produce‎different‎tyrosine‎
phosphorylation profiles. 
Representative graphs and blots for different PDGFβ receptor phosphorylation sites after transactivation by 
quinpirole and serotonin are shown above. In Fig 3.7.A the data represent the mean ± S.E.M for five independent 
experiments comparing direct activation by 1 ng/mL PDGF-BB and transactivation by 10 μM quinpirole. In          
Fig 3.7.B the data represent the mean ± S.E.M for five independent experiments comparing direct activation by      
0.1 ng/mL PDGF-BB and transactivation by 10 μM quinpirole. In Fig 3.7.C the data represent the mean ± S.E.M for 
three independent experiments comparing direct activation 0.1 ng/mL PDGF-BB and transactivation by 100 nM 
serotonin. Cells were lysed after treatment and were evaluated by western blotting. The results were analyzed for 
phospho-PDGFβ receptor 1021 (pY1021)  1009 (pY1009)  740 (pY740)  771 (pY771)  and 751 (pY751) 
immunoreactivity; the data were normalized to the non-treated-cells (vehicle) as a control and to total PDGFβ 
receptors expression. β-Actin served as a loading control.*/V shows statistically significant results with p < 0.05 
compared to non-treated-cells; */P shows statistically significant result with p < 0.05 compared to direct activation 
of the PDGFβ receptor with 1 ng/mL PDGF-BB. One-way ANOVA were used for statistical calculation.  
 
 
 
 
 
 
Fig. 3.7C 
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3.6 Infra-additive effects between direct activation by PDGF-BB and 
transactivation by serotonin  
We have examined and compared direct stimulation of the PDGFβ receptor by PDGF-BB with 
transactivated receptor by GPCR agonists. In order to examine whether co-treatment with a 
direct and a transactivation stimulus would synergistically increase PDGFβ receptor 
phosphorylation, SH-SY5Y cells were treated with serotonin (100 nM), PDGF-BB (0.1 ng/mL), 
or both for 5 minutes. Cells were lysed after treatment and were evaluated by western blotting. 
The data showed that co-treatment with 5-HT and PDGF-BB actually reduced the level of 
phosphorylation of Tyr740 and 771 compared to 5-HT treatment alone [Figure  3.8]. In other 
words, co-incubation was infra-additive rather than additive or synergistic. Akt is activated 
downstream of PDGFβ receptors. We analyzed p-Akt473 and p-Akt308 immunoreactivity as a 
measure of Akt activation after treatment with serotonin (100 nM), or PDGF-BB (0.1 ng/mL), or 
both. Despite the results with PDGFβ receptor phosphorylation  no significant increases in Akt 
phosphorylation were observed in any treatment conditions [Figure  3.9].  
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Figure  3.8 Infra-additive effects between direct activation and transactivation, and its effect on fold change in 
various‎phosphorylation‎sites‎of‎PDGFβ‎receptors‎ 
The results were analyzed for phospho-PDGFβ receptor 1021 (pY1021)  1009 (pY1009)  740 (pY740)  771 
(pY771), and 751 (pY751) immunoreactivity; the data were normalized to the non-treated-cells (vehicle) as a 
control and to total PDGFβ receptors expression. β-Actin served as a loading control. The data represent the mean ± 
S.E.M. for two independent experiments. Co-treatment with 5-HT and PDGF-BB reduced the level of 
phosphorylation of Tyr740 and 771 compared to 5-HT treatment alone. 
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Figure  3.9 Infra-additive effects between direct activation and transactivation, and its effect on Akt 
phosphorylation‎as‎a‎downstream‎effector‎of‎PDGFβ‎receptors‎ 
The results were analyzed for phospho-Akt (Ser473) and (Thr308) immunoreactivity. The data were normalized to 
the no-treated-cells (vehicle) as a control and to total Akt protein expression. β-Actin served as a loading control. 
There was attenuation in phosphorylation of Akt at Ser473 and Thr308 after application of two agonists together. 
The data represent the mean ± S.E.M. for two independent experiments. 
 
3.7 Downstream effectors activation by quinpirole and PDGF-BB 
Quinpirole treatment of SH-SY5Y cells results in the transactivation of PDGFβ receptors and the 
activation of several downstream signaling cascades. To evaluate the difference between the fold 
changes in the phosphorylation states of various effectors in downstream of PDGFβ receptors 
(Tyr1021), cells were treated with quinpirole (10 μM) or PDGF (1 ng/mL) for 10 minutes. 
Western blots were performed with phospho-ERK1/2 [Figure  3.10], phospho-Akt (Thr308) 
(Thr473) [Figure  3.11], phospho-c-Raf (Ser259) [Figure  3.12], phospho-PDK1 (Ser241)   
[Figure  3.13], phospho-PTEN (Ser380) [Figure  3.14], phospho-GSK (Ser9) [Figure  3.15], and 
phosphor-PLCγ1 (Tyr783) [Figure  3.16].  
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Our second null hypothesis was that there are no differences between downstream cascades of 
PDGFβ receptors after direct activation and transactivation. To evaluate this hypothesis the fold 
changes in the phosphorylation states of various effectors in downstream of PDGFβ receptors 
were examined. The fold change of p-ERK1/2 after direct activation compared to transactivation 
of PDGFβ receptors showed greater activation; however the differences were not statistically 
significant. There was almost 3-fold change in direct activation compared to transactivation 
[Figure  3.10]. The fold change increase in p-Akt (Thr308) and p-Akt (Ser473), as a part of PI3-
kinase/Akt pathway, compared to vehicle is greater for direct activation than transactivation of 
PDGFβ receptors and there were almost 2-fold changes in direct activation compared to 
transactivation for both phosphorylation sites [Figure  3.11].  
 
Phospho-c-Raf (Ser259), activated downstream of both MAPK/ERK1/2 and PI3-kinase/Akt 
pathways, showed a greater increase after transactivation compared to direct activation of 
PDGFβ receptors [Figure  3.12]. Phospho-c-Raf (Ser259) has a negative regulatory effect on both 
pathways. The p-PDK1 (Ser241), effector in PI3-kinase/Akt pathway, also showed a greater 
increase after transactivation compared to direct activation of PDGFβ receptors. There was no 
significant difference between non-treated cells and direct activation in phosphorylation of 
PDK1 [Figure  3.13]. PDK1 is responsible for phosphorylation of Akt at Thr308. PTEN, negative 
regulatory effector of PI3-kinase/Akt pathway, showed almost the same fold change in PTEN 
(Ser380) phosphorylation after direct activation and transactivation of PDGFβ receptors 
[Figure  3.14]. GSK-3β  effector in PI3-kinase/Akt pathway, showed slightly more fold change in 
its Ser9 phosphorylation site after direct activation of PDGFβ receptors via quinpirole compared 
to transactivation [Figure  3.15]. Activation of Akt has an inhibitory effect on GSK-3β 
phosphorylation. The phospho-PLCγ1  downstream for PLC pathway, showed a significant fold 
change after both direct activation and transactivation of PDGFβ receptors compared to non-
treated-cells [Figure  3.16]. Thus, based on our results, activation of downstream cascades of 
PDGFβ receptors after direct activation and transactivation are not identical. 
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Figure  3.10 Comparison between ERK1/2 fold change of phosphorylation site after transactivation and direct 
activation  
The p-ERK1/2 fold change after direct activation compared to transactivation of PDGFβ receptors showed more 
activation; however they did not show statistically significant differences with p < 0.05.The data were normalized to 
the non-treated-cells (vehicle) as a control and to total protein expression for ERK1/2. Then  β-Actin served as a 
loading control. The data represent the mean ± S.E.M. for two independent experiments. One-way ANOVA was 
used for statistical calculation. 
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Figure  3.11 Comparison between fold change of Akt phosphorylation sites after transactivation and direct 
activation  
The fold change increase in the p-Akt (Thr308) and p-Akt (Ser473) compared to vehicle is more in direct activation 
than transactivation of PDGFβ receptors. The data were normalized to the non-treated-cells (vehicle) as a control 
and to total protein expression for Akt. β-Actin served as a loading control. The data represent the mean ± S.E.M. 
for two independent experiments.  
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Figure  3.12 Comparison between fold change of phosphorylation of c-Raf at Ser259 after transactivation and 
direct activation  
The phospho-c-Raf (Ser259) as a phosphorylation site of c-Raf showed more increase in fold change after 
transactivation compared to direct activation of PDGFβ receptors. There were significant difference between 
phosphorylation of c-Raf after transactivation compared to direct activation and no-treated-cells. There was not any 
significant difference between non-treated-cells and direct activation in phosphorylation of c-Raf The data were 
normalized to the non-treated-cells (vehicle) as a control. Then  β-Actin served as a loading control. The data 
represent the mean ± S.E.M. for two independent experiments.  
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Figure  3.13 Comparison between fold change in PDK1 phosphorylation after transactivation and direct 
activation 
The p-PDK1 (Ser241) as a phosphorylation site of PDK1 showed more increase in fold change after transactivation 
compared to direct activation of PDGFβ receptors. The data were normalized to the non-treated-cells (vehicle) as a 
control. Then  β-Actin served as a loading control. The data represent the mean ± S.E.M. for two independent 
experiments.  
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Figure  3.14 Comparison between fold change in phosphorylation of PTEN at Ser380 after transactivation and 
direct activation 
PTEN showed almost the same fold change in PTEN (Ser380) phosphorylation after direct activation and 
transactivation of PDGFβ receptors. The data were normalized to the non-treated-cells (vehicle) as a control. Then, 
β-Actin served as a loading control. The data represent the mean ± S.E.M. for two independent experiments.  
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Figure  3.15 Comparison between fold change in phosphorylation of GSK-3β‎at‎Ser9‎after‎transactivation‎of‎
and direct 
GSK-3β showed slightly fold change increase (almost 0.5-fold) in its Ser9 phosphorylation site after transactivation 
of PDGFβ receptors via quinpirole compared to vehicle. The data were normalized to the non-treated-cells (vehicle) 
as a control. Then  β-Actin served as a loading control. The data represent the mean ± S.E.M. for two independent 
experiments.  
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Figure  3.16 Comparison‎between‎PLCγ1‎fold‎change‎of‎phosphorylation‎site‎after‎transactivation‎and‎direct‎
activation 
The p-PLCγ1 showed a significant increase in fold change after direct activation and transactivation of PDGFβ 
receptors compared to no-treated-cells. The data were normalized to the non-treated-cells (vehicle) as a control and 
to total protein expression for PLCγ1. Then  β-Actin served as a loading. The data represent the mean ± S.E.M. for 
two independent experiments.  
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 Chapter 4
Discussion 
 
4.1 Comparison between transactivation and direct activation  
Application of several GPCR agonists and PDGF-BB induced a significant increase in 
phosphorylation of the PDGFβ receptors at Tyr1021 in SH-SY5Y cell line compared to the basal 
level. Application of 0.1 to 1 ng/mL of PDGF-BB induced 10 to 100-fold increase in Tyr1021 
phosphorylation, whereas treatment of cells with GPCR agonists increased the phosphorylation 
state of Tyr1021 only 2-3 fold via transactivation of PDGFβ receptors [Figure  3.1]. However, 
despite significant differences in the phosphorylation level of the receptor, application of GPCR 
agonists compared to application of PDGF-BB did not show significant differences in inducing 
ERK1/2 phosphorylation: PDGF-BB only increased ERK phosphorylation ~ 2-fold more than 
the D2-family dopamine receptor agonist, quinpirole [Figure  3.2]. Thus, the higher 
phosphorylation of the receptor does not necessarily correlate with higher activation of the 
downstream effectors. In addition  other specific phosphorylation sites on PDGFβ receptors have 
the ability to induce MAPK/ERK activation, (see section 1.3.1.2.1). 
 
Several papers previously demonstrated the transactivation of PDGFβ receptors via dopamine 
receptors in various cells [24,143,146-150]. The ability of raclopride to block quinpirole-induced 
phosphorylation of the PDGFβ suggests that its effects are mediated via D2-family dopamine 
receptors [Figure  3.5]. The EC50 for quinpirole for activating D2-family dopamine receptors is 
0.57 nM in D293 cells stably expressing the dopamine D2 receptors and in rat brain [145]. Our 
dose-response curve showed that EC50 for quinpirole to transactivate PDGFβ receptors is 
approximately 5.3 μM [Figure  3.6]. Thus, the concentration of quinpirole required to 
transactivate PDGFβ receptors is nearly 10000-fold higher in our model.  
 
Direct activation of PDGFβ receptors by PDGF-BB increases Tyr1021 phosphorylation in a time 
dependent manner. After 20 minutes, the phosphorylation levels began to drop, likely due to the 
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action of tyrosine phosphatases and the early stages of receptor downregulation. In contrast, 
transactivated receptors showed a stable amount of phosphorylation at Tyr1021 over time after 
application of quinpirole or dopamine. This result could be due to the relatively weaker and 
continuous/prolonged level of transactivation on PDGFβ receptors in SH-SY5Y cells. 
Alternatively, the consistent amount of phosphorylation (over time) induced by transactivation 
could be due to the absence of same regulatory proteins and phosphatases responsible for 
regulating direct activation. It could be possible that transactivation stimulates its own regulatory 
proteins and phosphatases, but they have different characteristics compared to direct activation. 
Furthermore  despite the fact that downregulation of PDGFβ receptors after prolonged or 
excessive exposure to the ligand can attenuate the activity of the receptors, recent studies have 
shown that the desensitization and internalization of GPCRs not only are the process for 
terminating receptor activity, but are themselves signaling events [151,205]. Therefore, the acute 
transactivation of the PDGFβ receptors over 30 minutes did not show the high peak and 
attenuation in phosphorylation since transactivation is not dependent on downregulation of the 
PDGFβ receptors  and because internalization of the GPCRs may not terminate their activity 
[Figure  3.3].  
4.1.1 Phosphorylation‎of‎PDGFβ‎receptors‎by‎transactivation‎at‎tyrosine‎residues 
The intracellular domain of PDGF receptor consists of several tyrosine phosphorylation sites that 
can stimulate different downstream cascades when phosphorylated. PDGF receptors tyrosine 
phosphorylation sites act as docking sites for recruitment of signal transduction proteins that 
contain SH2 domains [152]. Five different phosphorylation sites containing Tyr740, Tyr751, 
Tyr771, Tyr1009, and Tyr1021 were examined to compare the effect of transactivation versus 
direct activation of PDGFβ receptor phosphorylation sites. These five phosphorylation sites are 
crucial sites in activating major downstream cascades of PDGFβ receptors. Our data showed that 
the phosphorylation profile of ligand-activated versus transactivated PDGFβ receptors is 
different and that direct activation of the PDGFβ receptor (1 ng/mL PDGF-BB) increases the 
level of total tyrosine phosphorylation to a greater extent than quinpirole (10 μM) at all sites 
[Figure  3.7A].  
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PDGF is a polypeptide that was purified first from human platelets [28]; it is available in alpha-
granules of circulating blood platelets. Usually, it is detectable at high concentrations in blood 
clots. The amount of PDGF in unclotted blood is less than 1 ng/mL, whereas the amount of 
PDGF in clotted blood serum is about 15 ng/mL [153]. In order to increase the physiological 
relevance of our ligand-activated versus transactivated PDGFβ receptor comparison  we used the 
lowest concentration of PDGF-BB possible. Previous data from our lab indicated that the lowest 
concentration of PDGF-BB that could increase phosphorylation of PDGFβ receptors (at 
Tyr1021) was between 0.05 and 0.1 ng/mL [154]. We repeated our experiment comparing the 
phosphorylation profile of ligand-activated versus transactivated PDGFβ receptors with an 
application of 0.1 ng/mL PDGF-BB to SH-SY5Y cells [Figure  3.7B,C]. A comparison between 
the phosphorylation profile of serotonin (100 nM) or quinpirole (10 μM)-transactivated PDGFβ 
receptors versus PDGF-BB (0.1 ng/mL)-activated PDGFβ receptors revealed different 
phosphorylation patterns for each phosphorylation site. Quinpirole resulted in significantly 
higher changes in the phosphorylation of PDGFβ receptors at Tyr751 and Tyr771 compared to 
ligand-activated PDGFβ receptors; however  there were no significant differences in 
phosphorylation of PDGFβ receptors at Tyr740  Tyr1009  and Tyr1021 [Figure  3.7B]. On the 
other hand  serotonin increased the phosphorylation of PDGFβ receptors at Tyr740 and Tyr771 
to a greater extent than ligand-activated PDGFβ receptors; however, there was no significant 
change in the phosphorylation of PDGFβ receptors at Tyr751  Tyr1009  and Tyr1021 
[Figure  3.7C]. In conclusion  the increase in PDGFβ receptor phosphorylation at Tyr740, 
Tyr751, Tyr771, Tyr1020, and Tyr1009 after application of quinpirole (10 μM) was less than the 
increase by PDGF-BB (1 ng/mL) [Figure  3.7A]; however, quinpirole (10 μM) can increase 
PDGFβ receptor phosphorylation state at Tyr1021, Tyr751, and Tyr771 to a greater extent than 
PDGF-BB (0.1 ng/mL) [Figure  3.7B], and serotonin (100 nM) can increase PDGFβ receptor 
phosphorylation state at Tyr740, Tyr751, and Tyr771 to a greater extent than PDGF-BB         
(0.1 ng/mL) [Figure  3.7C]. The table below shows the phosphorylation profiles for the PDGFβ 
receptor after different ligands were applied. Interestingly, even using different concentrations of 
PDGF-BB itself resulted in different phosphorylation profiles. 
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PDGF-BB (1 ng/mL)        Y751>Y1009=Y1021>Y740>Y771 
PDGF-BB (0.1 ng/mL)     Y1009>Y1021>Y740>Y751>Y771 
Quinpirole‎(10‎μM)‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎ Y751> Y1009=Y1021>Y771>Y740 
Serotonin (100 nM)                   Y740> Y771>Y1009>Y1021>Y751 
 
Previous studies showed that, in CHO-D4 cells, dopamine (1 μM) increase the total tyrosine 
phosphorylation level of PDGFβ receptor less than PDGF-BB (10 ng/mL) [155]; and Tyr716, 
Tyr740, Tyr751, and Tyr1021 showed a greater phosphorylation following application of   
PDGF-BB (10 ng/mL) compared to dopamine (1 μM) [155]. Interestingly, Tyr857, the 
phosphorylation site involved in catalytic activity of the kinase, was not phosphorylated 
following transactivation in CHO-D4 cells [155]. Tyr857 has a primary role in tyrosine kinase 
activity of PDGFβ receptors in vitro, but not in vivo [156,52]. The existence of a kinase(s) that 
could compensate for the lack of intrinsic receptor kinase activity may explain why PDGFβ 
receptors can be phosphorylated without Tyr857 phosphorylation [156]. Phosphorylation of 
Tyr857 keeps PDGFβ receptor activated even after dissociation of PDGF-BB  [52].  Mutation in 
Tyr857, resulting in low or no kinase activity, caused a significant elevation in phosphorylation 
of PDGFβ receptors at Tyr771 compared to wild-type receptors and non-treated-cells [156]. 
Therefore, the fact that quinpirole (10 μM) and serotonin (100 nM) increased the 
phosphorylation state of Tyr771 to a greater extent than PDGF-BB (0.1 ng/mL) could be because 
they caused no phosphorylation of Tyr857 after transactivation compared to direct activation of 
the PDGFβ receptors.  
 
PDGFβ receptors with mutations of Tyr857 are unable to induce full phosphorylation and 
activation of SHP-2, Akt, and ERK1/2 in porcine aortic endothelial (PAE) cells [52]. This results 
in decreased cell proliferation and increased cell apoptosis; however cells with mutation in 
Tyr857 showed considerable residual ability for PDGF-stimulated DNA synthesis, almost 50% 
compared to wild type receptors. Compared to PDGF-BB (1 ng/mL), serotonin (100 nM) 
elevated the phosphorylation state of Tyr740 and Tyr751, which are the docking sites for       
PI3-kinase/Akt, to a greater extent. Tyr1009 showed the same level of phosphorylation following 
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quinpirole or serotonin application in SH-SY5Y cell line compared to the application of     
PDGF-BB (0.1 ng/mL). Because SHP-2 binds to phosphorylated Tyr763 and Tyr1009 [28,59], 
phosphorylation of Tyr763 might be affected by transactivation that leads to decrease in 
activation of SHP-2.  
 
One reason why the higher phosphorylation states on PDGFβ receptor did not result in the higher 
activation of downstream effectors could be due to the activation of Tyr857. Mutations in 
Tyr857 result in an impairment of the phosphorylation and activation of SHP-2 [156], which 
selectively dephosphorylates Tyr740, Tyr751, and Tyr771 on PDGFβ receptors [28]. However, 
dephosphorylation activity of SHP-2 is not a switch-off event; indeed, it seems that SHP-2 acts 
as a regulatory effector that intensifies the receptor signals by keeping the tyrosine 
phosphorylation sites at a high level of dynamic turnover [59]. Thus  PDGFβ receptor signal 
transduction is dependent not only on the level of tyrosine phosphorylation but also on the 
degree of dynamic turnover of phosphorylation sites and regulatory effectors. Since Tyr857 was 
not phosphorylated following transactivation, this fact could explain the importance of both 
tyrosine kinases and phosphatases in PDGFβ receptor downstream signalling pathways. In 
addition, another compensating kinase could regulate transactivation of PDGFβ receptors rather 
than identified regulatory mechanisms for direct activation. 
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Figure  4.1 Phosphorylation‎sites‎on‎PDGFβ‎receptors‎and‎downstream‎pathways‎ 
 
These data suggest that not only does GPCR-induced transactivation result in a different 
phosphorylation profile of the PDGF receptor compared to direct activation, even different 
concentrations of PDGF-BB (0.1 versus 1 ng/mL) can induce different phosphorylation profiles.  
4.1.2 Infra-additive effects between serotonin receptors and‎PDGFβ‎receptors 
In the “synergy experiment” we found that in SH-SY5Y cells, application of low concentration 
of quinpirole and PDGF-BB the same time did not show any difference in phosphorylation site 
of Tyr1021 and Tyr1009. However, concomitant application of quinpirole and PDGF-BB 
increased the phosphorylation site in Tyr740 and Tyr771 compared to direct activation but 
decreased it compared to transactivation. Interestingly, this same treatment decreased the 
  74 
phosphorylation of Tyr751 to a level lower than each of treatment separately as was in fact 
below the control (untreated) cells. It could be because of activation of Tyr857 and SHP-2 in 
result of direct activation of PDGFβ receptors after concomitant application of GPCR agonist 
and PDGFβ receptor agonist. Tyr740 and Tyr751 are the docking sites for PI3-kinase/Akt 
pathway; the decrease of the phosphorylation in these Tyr residues after concomitant application 
of drugs results in decrease in phosphorylation state on Akt at Thr308 and Ser473. The table 
below shows the effector protein profiles for the PDGFβ receptor after direct activation     
(PDGF-BB 1 ng/mL) versus transactivation (quinpirole 10 μM) of the PDGFβ receptors.  
 
p-ERK1/2 PDGF-BB > Quinpirole > non-treated-cells 
p-Akt(Thr308) PDGF-BB > Quinpirole > non-treated-cells 
p-Akt(Ser473) PDGF-BB > Quinpirole > non-treated-cells 
p-c-Raf(Ser259) Quinpirole > PDGF-BB > non-treated-cells 
p-PDK1(Ser241) Quinpirole > PDGF-BB > non-treated-cells 
p-PTEN(Ser380) Quinpirole > PDGF-BB > non-treated-cells 
p-GSK-3β(Ser9) PDGF-BB > Quinpirole > non-treated-cells 
p-PLCγ1(Y783) PDGF-BB > Quinpirole > non-treated-cells 
 
4.1.3 MAPK/ERK pathway and transactivation 
Since the activation of the downstream pathways of PDGFβ receptors following application of 
PDGF-BB (0.1 ng/mL) was not sufficient to significantly increase ERK1/2 phosphorylation,       
1 ng/mL PDGF-BB was used. Phosph-Tyr740, -Tyr751, and -Tyr771 are the main binding sites 
for Shc that results in activation of the Ras/MAPK pathway and the phosphorylation of all of 
these sites was elevated after the application of serotonin or quinpirole. However, the increase in 
phospho-Tyr771, which is a docking site for GAP, also has a negative regulatory effect on Ras-
ERK1/2 pathway [28,53]. The net phosphorylation of ERK1/2 is based on the net 
phosphorylation of the receptor as well as the decrease in the activation of SHP-2 and 
phosphorylation of Tyr857. Other pathways independent of PDGFβ receptors might also be 
  75 
involved in ERK1/2 activation. In addition  elevation in phosphorylation of PDGFβ receptor at 
Tyr771 after application of serotonin and quinpirole compared to direct activation 
[Figure  3.7B,C] results in the activation of GTPase for Ras and a decrease in ERK1/2 activation. 
The adaptor proteins Nck can bind to Sos after activating by phosphorylated Tyr751 in PDGFβ 
receptor, which could be a substitute pathway for activation of Ras/MAPK/ERK pathway [157]. 
Thus, a robust phosphorylation of Tyr751 after transactivation could be another alternative 
pathway in stimulating MAPK/ERK pathway. 
 
It is possible that despite apparent similarities between direct ligand activated versus 
transactivated PDGFβ receptor with respect to ERK1/2 phosphorylation  each signaling 
mechanism may use different pathways to reach ERK. Raf plays a key role in controlling 
ERK1/2 activation [158]. The Raf family consists of three isoforms: a-Raf, b-Raf, and c-Raf. Raf 
kinases are substrates for Ras after activation by PDGFβ receptors. Binding of Ras-GTP to the 
active site of Raf results in conformational changes and recruits Raf to the cell membrane, which 
changes its phosphorylation pattern and stimulates its kinase activity [158]. Ser43, Ser621, and 
Ser259 are phosphorylation sites on Raf, all of which negatively regulates Raf kinase activity 
when phosphorylated [160]. Positive regulation of c-Raf is depends on protein phosphatase 2 
(PP2), which is serine/threonine phosphatase [160]. Dephosphorylation of Ser259 is associated 
with Raf activation and occurs as it associates with the cell membrane. Ser621 phosphorylation 
also has a regulatory effect on kinase activity and membrane translocation of Raf [160].  
Throughout the activation of Raf, Ser259 remains dephosphorylated, but Ser621 is 
phosphorylated quickly [160]. c-Raf (Raf-1) is normally a cytoplasmic inactive kinase bound to 
adaptor protein 14-3-3 and c-Raf activation involves protein 14-3-3 dissociation, Ser259 
dephosphorylation, and c-Raf recruitment to the cell membrane. Raf activation then leads to 
MEK phosphorylation and activation, which in turn phosphorylates and activates ERK1/2. The 
biological response of c-Raf/ERK1/2 pathway is associated with the strength and duration of the 
activation [161,162]. 
 
  76 
Compared to ligand activated receptors  transactivated PFGFβ receptors resulted in a higher 
phosphorylation of c-Raf at Ser259. This result lets us speculate that quinpirole could activate 
the ERK1/2 to a reduced extent than direct activation of the PDGFβ receptors. Our results for 
ERK1/2 activation after application of quinpirole and PDGF-BB supported this claim: it showed 
that PDGF-BB (1 ng/mL) induced phosphorylation and activation of ERK1/2 to a greater extent 
than quinpirole [Figure  3.10]. Interestingly, the phosphorylation c-Raf at Ser259 after application 
of quinpirole is higher than in non-treated cells (baseline), whereas the phosphorylation of 
Ser259 after direct activation is almost at the same level of baseline [Figure  3.12]. 
 
In addition, we must consider that the activation of MAPK/ERK pathway involves multiple 
pathways including direct PDGFβ receptor-Grb2-Sos complexes  PDGFβ receptor-Shc-Grb2-Sos 
complexes  PDGFβ receptor-SHP-2-Grb2-Sos complexes, as well as Raf- and Ras-independent 
pathways [161,162]. For a better understanding of the effect of transactivation on ERK1/2, an 
evaluation of each of these pathways and their association with downstream cascades of 
dopamine receptors or PDGFβ receptors is required. 
 
Ras/MAPK 
pathway 
Direct activation of Grb2-Sos Grb2 Tyr716/Tyr775 
Indirect activation of Grb2-Sos 
Shc Tyr579/Tyr740/ Tyr751/Tyr771 
SHP-2 Tyr763/Tyr1009 
 
Several papers have examined the phosphorylation of PDGFβ receptors and downstream 
effectors (primarily ERK1/2, but also Akt) after transactivation [24,155,163,164]. However, it is 
important to consider ERK1/2 as a downstream effector of GPCRs as well. So, the question 
remains whether ERK1/2 activation after quinpirole application is due exclusively to PDGFβ 
receptor transactivation or additional, RTK-independent pathways. Thus, for comparing the 
increase of ERK1/2 phosphorylation in direct activation and transactivation, ruling out the effect 
of GPCRs on ERK phosphorylation is important. The most direct way of achieving this is to 
measure ERK1/2 phosphorylation after GPCR agonist treatment in the presence of RTK 
inhibitors. Transactivation of PDGFβ receptors by dopamine D4 receptors activates ERK1/2, in 
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hippocampal neurons and fibroblasts [24,143,146-150]. Recently, our lab showed that there 
might be another possible parallel mechanism for ERK1/2 activation through GPCR-induced 
PDGF receptor transactivation [165]; indeed, this study and other studies suggested that 
functional oxidase might be necessary for transactivation [206]. Thus, NADPH oxidase 
components were introduced to stimulate ERK1/2 activation in a parallel mechanism with 
transactivation of PDGF receptors [165]. PDGFβ receptor transactivation also suppresses 
NMDA receptor activity [114]. Oak et al. used an in vitro Elk1 (ETS domain-containing protein) 
kinase assay to evaluate activation of ERK1/2 after transactivation [24]. Tyrphostin A9, a 
receptor tyrosine kinase inhibitor, and AG1295, a selective PDGF receptor tyrosine kinase 
inhibitor, both blocked activation of ERK1/2 via dopamine D4 receptors [24].  
 
All D2-family dopamine receptors are thought to couple to Gαi/o. However, differences within the 
class of receptors have been observed. Inhibiting Gβγ subunits prevents dopamine D4 receptors 
regulating ERK1/2 pathway but not dopamine D2 receptors [24]. In addition, dopamine D4 
receptors and dopamine D2 receptors are coupled to the different Gα subunits [144]. Thus, 
transactivation mechanism(s) may not be the same between all dopamine receptor subtypes 
[144]. In addition, various cell types and different initiating GPCRs for transactivating PDGF 
receptors might use similar but distinct mechanisms to stimulate transactivation. As our lab 
previously suggested, 5-HT could transactivate both PDGFβ receptors (and TrkB) receptors 
through increase in intracellular calcium, activation of PKC, and Src. Activation of PKC and Src 
results in activation of NADPH oxidase subunits which in turn produces ROS. The production of 
ROS results in oxidation and inactivation of phosphotyrosine phosphatases, resulting in an 
inhibiting dephosphorylation of PDGFβ receptors and TrkB receptors [165,206].  
4.1.4 PI3-kinase/Akt pathway and transactivation  
Phosphorylation of PI3-kinase at p85 subunit leads to phosphorylation of catalytic subunit p110. 
Once activated, PI3-kinase phosphorylates PtdIns(4,5)P2 and produces a novel phosphoinositide 
PtdIns(3,4,5)P3, which in turn binds to PH domains of PDK1 and Akt/PKB. PtdIns(3,4,5)P3, 
which is anchored to the membrane, translocates Akt to the plasma membrane where Thr308 is 
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phosphorylated by PDK1. The phosphatase and tensin homolog (PTEN) dephosphorylates and 
converts PtdIns(3,4,5)P3 to PtdIns(4,5)P2 and acts as an off-switch in the Akt pathway. Full 
activation of Akt requires phosphorylation at both Thr308 and Ser473 and it is the mammalian 
target of rapamycin (mTOR) that phosphorylates Akt at Ser473. Active Akt phosphorylates 
many downstream targets, resulting in proliferation, cell migration and adhesion, protein 
synthesis, survival, insulin action, neuroprotection, and NO synthesis. Akt inhibits cell-cycle 
inhibitors in order to promote proliferation. Akt promotes cell survival by phosphorylation and 
inhibition of pro-apoptotic proteins such as Bad, Bax, Bim, MDM2, and FOXO1/3/4. This 
process, in conjunction with signaling through PLC/PKC and MAPK/ERK pathways, promotes a 
protective effect against apoptosis [208,209]. 
 
Tyr740 and Tyr751 are the primary tyrosine residues of PDGFβ receptors that are directly 
involved in the activation of PI3-kinase [28]. The phosphorylation of both tyrosines showed 
robust phosphorylation after application of serotonin compared to PDGF-BB [Figure  3.7C]. The 
application of quinpirole also increased the phosphorylation of PDGFβ receptors at Tyr751 to a 
greater extent than PDGF-BB (0.1 ng/mL) and at Tyr740 to the same level as PDGF-BB 
[Figure  3.7B].  However, increasing the concentration of PDGF-BB to 1 ng/mL increased the 
phosphorylation of PDGFβ receptors at Tyr740 and Tyr751 to a greater extent than quinpirole 
[Figure  3.7A]. These data is compatible with our results on Akt phosphorylation after direct 
activation and transactivation [Figure  3.11]. 
 
PDK1 (Ser241) phosphorylation showed a higher increase following transactivation compared to 
direct activation; however this difference was not significant [Figure  3.13]. The fold change in 
phosphorylation of PTEN was similar following direct activation or transactivation. Even though 
the fold change in phosphorylation of Akt was greater during direct activation compared to 
transactivation [Figure  3.11], the activation of the negative regulatory effector, PTEN, of Akt 
showed the same strength in direct activation and transactivation. Thus, the regulatory system 
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seems to be different in direct activation compared to transactivation: direct activation results in 
greater phosphorylation on Akt. 
 
Once activated, the PI3-kinase pathway phosphorylates Akt at Thr308 and Ser473 via PDK1 and 
PDK2/rictor-mTOR, respectively [166]. Akt, (also called PKB) is a serine/threonine protein 
kinase belonging to the adenine-guanine-cytosine (AGC) kinases family. Thr308 is located in the 
kinase domain, and Ser473 is located in the regulatory domain. The Akt pathway is important for 
cell growth, proliferation, and cell survival. Akt is activated downstream of both GPCRs and 
RTKs. Phosphorylation at Thr308 and Ser473 was increased following application of quinpirole 
compared to control [Figure  3.11] and the application of PDGF-BB (1 ng/mL) increased 
phosphorylation states at both Thr308 and Ser473 to a greater extent than transactivation by 
quinpirole [Figure  3.11].  
 
The primary question is how much of Akt pathway activation belongs to downstream pathways 
of PDGFβ receptors and how much belongs to downstream pathways of D2-family dopamine 
receptor. Dopamine D2/3 receptors induce the activation of Akt shortly after application of 
dopamine in the dorsal striatum of rat [167]. In the dorsal stratum and NAcc, preincubation with 
raclopride inhibits phosphorylation of Akt (Ser473 and Thr308), and GSK3α/β at Ser9; 
suggesting that dopamine D2 receptors are involved in Akt activation [167]. Activation of Akt 
leads to phosphorylation and inactivation of GSK3α/β at Ser21 and Ser9. Prolonged stimulation 
of dopamine D2 receptors by dopamine or quinpirole leads to an attenuation in Akt activity, 
especially at the level of Thr308 phosphorylation, likely due to receptor binding and 
desensitization by β-arrestin2 and phosphatase A2 activity [167]. Inhibition of Akt results in 
GSK3 activation in the mouse striatum, rat frontal lobe, and zebrafish brain [168,169]. 
Modulation of cAMP does not have any effect on Akt pathway [169]; however, dopamine D2 
receptor-dependent β-arrestin regulates the activation of Akt/GSK3 [166]. The serine/threonine 
protein phosphatase 2A (PP2A) inactivates Akt pathway by dephosphorylating Thr308 and 
Ser473 [170]. 
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Our results indicated an increase in the phosphorylation of Akt at both Thr308 and Ser473 
following direct activation or transactivation [Figure  3.11]. In addition, a similar fold-increase in 
the phosphorylation state of GSK3β after application of PDGF-BB and quinpirole was observed 
[Figure  3.15]. The difference between previous observations and our experiments could be due 
to the duration of experiments. Our experiments were based on acute activation of the receptor 
(usually from 5 to 10 minutes); however, the other experiments were based on longer time 
periods (usually more than 30 minutes). Downstream cascades of GPCR-mediated by G-protein 
have a fast onset and a short duration because of receptor desensitization. However  β-arrestin 
signaling has a slower onset and a prolonged duration [166]. Furthermore, other studies 
examining the phosphorylation and activation of Akt in CHO cells expressing human dopamine 
D2 and D3 receptors after short-term (5-10 minutes) exposure to dopamine or quinpirole showed 
similar results to ours [171] [Figure  4.2].  
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Figure  4.2 Activation and inhibition of Akt pathway 
 
Raf is an intermediate effector in signal transduction pathways that promote survival and protect 
cells from apoptosis. In the Raf/MAPK/ERK pathway, phosphorylation of Ser259 regulates the 
kinase activity of Raf. Ser259 phosphorylation results in inactivation of Raf because it promotes 
Raf binding to 14-3-3 proteins. Akt directly phosphorylates Raf at Ser259 and creates a binding 
site for a negative regulator of Raf and decreases the kinase activity of Raf [160]. In addition, 
Akt, by phosphorylation of Bad and FKHRL1 (forkhead transcription factor) indirectly 
stimulates the binding of 14-3-3 protein to Raf, again leading to its inactivation [162]. Raf 
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promotes anti-apoptotic effects by binding to Bcl-2, stimulating BAD phosphorylation, 
activating PI3-kinase, and inhibiting apoptosis signal-regulated kinase 1 (ASK-1). Raf kinase, 
located at plasma membrane activates ERK signaling, and mitochondrial Raf regulates anti-
apoptotic pathways [162]. This cross-talk between downstream pathways alters the biological 
responses of cells from cell-growth to proliferation in MCF-7 cells; moreover, it can modulate 
differentiation [172]. On the other hand, ERK1/2 stimulates mTOR leading to phosphorylation of 
Akt at Ser473 [173]. An increase in phosphorylation of c-Raf at Ser259 following transactivation 
compared to direct activation of PDGFβ receptors was observed [Figure  3.12], whereas 
phosphorylation and activation in Akt following transactivation are less than direct activation. 
Thus, transactivation is a cross-talk not only between two pathways (ERK and Akt) but between 
two receptors (dopamine D2 receptor and PDGFβ receptor). The presence of other regulatory 
pathways and parallel downstream pathways that are activated through transactivation 
phenomena could elucidate more pieces of transactivation puzzle.   
4.1.5 PLCγ1 pathway and transactivation 
PLCγ1 binds to PDGFβ receptors at Tyr1021 (with high affinity) and Tyr1009 (with low 
affinity) to activate downstream signaling pathways that lead to cell growth, migration, and other 
pathways triggered by calcium signaling [28,174]. There exists different expression patterns for 
PLCγ isoforms in the human body: PLCγ1 is distributed in almost all cells  whereas PLCγ2 is 
mainly expressed in spleen and thymus [175]. In examining PLCγ phosphorylation as a marker 
for PLCγ activation, we observed no phosphorylation of phospho-PLCγ2 (Tyr1217) or phospho-
PLCγ2 (Tyr759)  despite the fact that we detected the presence of PLCγ2 in SH-SY5Y cell line. 
These results could be due to PLCγ2 activation by non-receptor protein tyrosine kinases, such as 
BCR and TCR. 
 
Significant increases in the phosphorylation of PLCγ1 at Tyr783 were observed in both ligand-
activated and transactivated receptors compared to baseline [Figure  3.16]. The PLCγ1 pathway 
plays a major role in mitogenicity and cell migration. Activation of this pathway also promotes 
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neuroprotection by regulating intracellular Ca
+2
 signaling and via the inhibition of NMDA and 
GABAA receptors [116]. 
4.1.6 Other important results 
PDGFβ receptor has two pools of receptors [143] and both of them are expressed in significant 
quantities. One pool is glycosylated and plasma membrane-localized and is ~180 kDa [176]. The 
other is intracellular, non-glycosylated  immature PDGFβ receptor (~140 kDa) in humans [177]. 
The plasma membrane receptors bind to PDGF-BB and may undergo internalization and 
degradation [178,179]. Downregulated PDGF receptor remains phosphorylated for less than two 
hours after ligand activation. Dopamine D4 receptors have been shown to transactivate both cell 
membrane-localized mature PDGFβ receptors and intracellular immature PDGFβ receptors  
whereas classical ligand activation can activate only surface receptors [143,180]. In fact, after 
application of quinpirole  increased phosphorylation of intracellular immature PDGFβ receptors 
at Tyr1021 to a greater extent than in non-treated cells was observed [Figure  4.3].  
 
 
 
Figure  4.3 Phosphorylation‎of‎intracellular‎immature‎PDGFβ‎receptors‎at‎Tyr1021 
Incubating cells with the glycosylation inhibitor tunicamycin overnight can prevent                     
n-glycosylation and results in a disappearance of surface localized mature PDGFβ receptors 
[24,143] and is a useful tool for comparing the phosphorylation profile and downstream effector 
activation of mature versus immature receptors after transactivation. 
4.1.7 Potential physiological relevance of transactivation to neurodegenerative diseases and 
psychiatric disorders 
In the last decade, the study of neurological disorders has revealed the importance of 
neurogenesis and synaptogenesis in the pathophysiology and treatment of neurodegenerative 
100μM     30μM      10μM       3μM        1μM       300nM   100nM        V 
180kDa 
140kDa 
Quinpirole 
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diseases such as Alzheimer‟s and Parkinson's disease. PDGF is an important neurotrophic factor 
for regulating neuronal proliferation and growth as well as the stimulation and regulation of 
neurogenesis and synaptogenesis. In neurodegenerative and psychiatric illness, both 
neurogenesis and synaptogenesis can be significantly impaired. In addition, a high level of 
angiogenesis has been found in tissues with nutrient-deprived conditions due to regulate 
oxidative metabolism upon replacement of nutrients and oxygen [181]. Interestingly, tissues with 
high levels of metabolic activity have low level of angiogenesis due to consumption of fatty 
acids for energy [181].  
 
The application of neurotrophic factors improves neuronal function in in vivo models of 
Alzheimer‟s disease [32,182] and can also rescue motor neurons and increase motor performance 
in Parkinson‟s models [183]. Although these studies demonstrate the effectiveness of using 
neurotrophic factors as therapeutic tools to treat neurodegenerative diseases, there are several 
barriers that prevent the use of neurotrophins as a treatment strategy: 1) they do not passively 
diffuse across the blood-brain barrier (BBB), 2) they need to be administered parenterally, and  
3) at high concentrations they may promote unregulated cell growth [184,185]. Unlike large 
neurotrophic factors that do not cross the BBB, small organic molecules are used frequently to 
target GPCRs in the brain without the risk of glioma and other serious adverse reactions. Finding 
small molecules that could transactivate PDGFβ receptors could be a major step toward a more 
effective and safer therapy for neurodegenerative diseases.  
 
Other neurotrophins such as nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3), are expressed mainly in the hippocampus and cortex and 
stimulate the survival of cholinergic neurons in the central nervous system. Because the 
hippocampus and cortex are important for memory and cognition, promoting their activity 
through transactivation may not only help neuron survival but also increase synaptic function. 
Transactivation of PDGFβ receptors reduces neuronal excitotoxicity by inhibiting NMDA 
receptors [144,191]. The neuroprotective effects of PDGFβ receptors depend on the inhibition of 
NMDA receptors and the induction of pro-survival genes via GSK3β and PI3-kinase/Akt 
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pathway [186]. PDGF also exerts neurotrophic effects on dopaminergic and GABAergic 
systems.  
4.2 Semantics: distinguishing receptor transactivation & gene transactivation 
GPCR-induced transactivation of PDGF receptors is a complex process and depends on various 
factors, including the cell type, the cellular environment, the availability of downstream effectors 
and proteins, the type and class of GPCRs, and the type of RTKs. Cross-communication between 
GPCRs and RTKs is initiated via GPCR ligands result in stimulation of either the upstream or 
the downstream pathways of RTKs. However cross-talk between GPCRs and RTKs is not a one 
way phenomenon. Indeed, transactivation of RTKs by GPCRs sometimes results in the 
recruitment of effectors and scaffold proteins that belong to downstream pathways of RTKs. 
 
Whenever the term transactivation is searched in databases such PubMed, most articles are about 
gene transactivation, which means the induction of gene expression. This term was first 
introduced by Thomas, R. 1970 [187]. On the other hand, RTK transactivation is considered one 
type of cross-talk between receptors. Usually  the terms “receptor transactivation” or “RTK 
transactivation” is used for GPCR-induced transactivation of RTKs; this process was first 
described by Daub, H. et al. 1996 [132]. However, even within the term “RTK transactivation”  
at least two common mechanisms are described: ligand-dependent and ligand-independent 
transactivation. In ligand-dependent transactivation, the activation of the GPCR results in the 
extracellular release of the growth factor ligand and subsequent direct activation of the RTK. 
This model is also called triple-membrane-passing-signaling (TMPS). Ligand-independent 
transactivation is the type of pathway discussed in this work. Finding a specific name for each of 
these processes would help future research and provide clarity. As a suggestion we could 
consider “gene transinduction” instead of “transactivation” for gene and “cross-talk” as a general 
term for the communication between two receptors. We could use “TMPS” for the ligand-
dependent model of GPCR-induced RTKs transactivation and “Second-Receptor-Downstream-
Transstimulation” (SRDT) or “Second-Receptor-Intracellular-Transstimulation” (SRIT) for 
ligand-independent model of GPCR-induced RTKs transactivation. 
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4.3 Fundamental questions (and potential answers) about transactivation 
1. Why do cells have two similar pathways to regulate and activate RTK receptors? 
Previously, it was assumed that receptors acted in isolation, depending on their own ligands to 
transduce extracellular signals into the cells. Over the past decades evidence points to intricate 
network interaction between various families of receptors and their downstream cascades. For 
example, protein kinases identified with one specific pathway may have the ability to 
phosphorylate other proteins associated with other downstream signaling pathways. RTK 
transactivation gives the opportunity to the cells to integrate diverse signals from different 
receptors and provides intricate network control over modulatory process of the cell functions 
including cell growth, differentiation, proliferation, and survival. Transactivation could be an 
opportunity for the cells to modulate a distinct stimulus into multiple pathways by taking 
advantage of downstream pathways of different receptors. In addition, when neurotrophin levels 
in CNS are reduced, mechanisms such as transactivation could compensate for survival and 
growth activity of neurotrophins, and this process could be one of the reasons for the existence of 
transactivation in the body [199]. 
2. Why do cells in the body require transactivation at all since RTKs can be activated by 
their ligands directly?  
Our results and other have demonstrated that transactivation may result in neuroprotection by 
activating pathways downstream of PDGF receptors. These neuroprotective effects involve the 
PI3-kinase/Akt pathway and PLC/NMDA pathway.  
 
Another reason for existence of transactivation could be because GPCR activation may be 
achievable on shorter time scales than activation of RTKs directly, particularly if de novo 
synthesis of growth factor is required. For example  transactivation of PDGFβ receptors by 
angiotensin II (Ang II) type 1 receptors (AT1R), type 2 receptors (AT2R)  and β2 adrenergic 
receptors, can induce rapid activation of ERK1/2 which in turn regulates biophysical hemostasis. 
Phospho-ERK1/2 is also one of the immediate downstream components for EGF receptors. In 
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cardiogenic shock, the renin-angiotensin system must react within seconds to control the blood 
pressure and could also stimulate the downstream pathways of several RTKs over a very short 
time frame [188]. 
 
The signal strength and duration of PDGF receptors are regulated by relatively rapid 
desensitization and downregulation of the receptors. Exposure of the PDGF receptor (or other 
RTKs) to high concentrations of ligand or long term exposure to ligand results in endocytosis of 
the receptors from the cell surface and subsequent degradation of the receptors and their bound 
ligands. This will reduce the total number of the cell surface receptors until they can be 
replenished by new receptor protein synthesis. Not all RTK internalization leads to signal 
termination. For example, EGF receptors may retain their ability to initiate signaling pathways 
even after internalization [189]. Similarly, it was believed that endocytosis of GPCRs led to 
signal termination; however, recent studies have shown some signaling pathways associated with 
GPCRs actually depend on endocytosis for maximal signaling. For example, activation of 
ERK/MAPK via the GPCR agonists, lysophosphatidic acid (LPA) and isoproterenol, requires 
endocytosis. In addition, PI3-kinase/Akt signaling by LPA requires activation of both membrane 
receptors and endosomal compartment receptors [190]. Indeed, GPCR endocytosis is not only a 
mechanism for signal desensitization, but also a mechanism for additional signal transduction 
pathways specially initiating transactivation. Interestingly  transactivation of PDGFβ receptors 
via dopamine receptors increases the phosphorylation and activity of both cell-surface localized, 
mature glycosylated PDGFβ receptors and intracellular  immature PDGFβ receptors [143,180]. 
Thus, downregulation, desensitization, or blocking the extracellular region of PDGF receptors at 
the cell surface might not prevent transactivation and signaling downstream of the PDGFβ 
receptor [148]. Ligand-induced activation of PDGFβ receptors requires receptor dimerization; 
Chi et al. suggested that PI3-kinase might be an intermediate effector for activating intracellular, 
monomeric PDGFβ receptors through transactivation. These findings suggest that dimerization is 
not required for PDGFβ receptor activation. Monomeric PDGFβ receptors can signal to 
downstream pathways such as the ERK1/2 pathway [155].  
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Transactivation provides a mechanism in the body for receptors located remotely from other 
receptors to exert regulatory effects. For example  dopamine at low concentration (< 50 μM) can 
potentiate NMDA receptor-mediated responses via activation of dopamine D1 receptors and 
dopamine at high concentration (> 50 μM) can depress NMDA receptor-mediated responses by 
activation of dopamine D2 receptors [114]. Although, it is improbable that synaptically released 
endogenous dopamine can reach excitatory glutamatergic synapses at a high enough 
concentration to exert inhibitory effects, the ability of dopamine receptors to transactivate PDGF 
receptors allows for an alternative route to regulate glutamatergic synapses. Transactivation of 
PDGFβ receptors by dopamine D2/4 receptors inhibits NMDA receptor currents in a 
Ca
+2
/calmodulin-dependent manner [114]. The ability of dopamine D2/4 receptors induce 
transactivation of PDGFβ receptors provides an opportunity for dopaminergic system to regulate 
excitatory synapses that are located remotely from them [114]. Thus, GPCR-induced 
transactivation of PDGFβ receptors may play a major role in the acute modulation of the 
synaptic transmission.  
 
3. What is the relevance of RTK transactivation by GPCRs in disease?  
Making a link between specific GPCR agonist(s) and the downstream signaling pathways of the 
PDGF receptor might help to identify specific pathological responses that could lead to the novel 
therapeutic targets. Since dopamine, GABA [117], and NMDA receptors [116] are targets for 
PDGF and PDGF receptors as a neurotrophic agent, it can be a therapeutic choice in treatment of 
neurodegenerative diseases  especially Parkinson‟s and Alzheimer‟s diseases. In experimental 
animal models of Alzheimer‟s  Parkinson‟s  Huntington‟s disease  and stroke  robust expression 
in PDGF and PDGF receptors in the lesioned of brain is reported [186].  
 
Regulating NMDA receptor currents is one way for inhibiting neurotoxicity in various 
neurological disorders. The acute excitotoxicity of the NMDA receptors due to the high 
concentration of glutamate immediately after ischemic and injury of the brain last for a short 
period of time [112]. Thus, NMDA receptor antagonists need to have a short half-life in order to 
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act as neuroprotective agents [112]. Currently, commercial NMDA receptor antagonists are 
unlikely to have this characteristic; however, unlike direct NMDA receptor antagonists, drugs 
with anti-NMDA receptor current effects may be better tolerated [112]. Normal physiological 
activation of NMDA receptors occurs during strong postsynaptic depolarization; however, 
moderate long-lasting depolarization results in chronic excitotoxic NMDA receptor activation 
[112]. A major need exist for NMDA receptor antagonists that provide protection against 
excitotoxicity but leave normal physiological function of NMDA receptors intact. PDGF-BB and 
PDGFβ receptors cause a long lasting inhibition of NMDA receptor-dependent EPSPs and 
GABAA-dependent IPSCs [49,116,117]. PDGF-BB has a selective inhibitory effect on NR2B- 
and not NR2A-containing NMDA receptor currents. PDGF-BB application reduces the 
expression and phosphorylation state of NR2B subunits. Thus, the neuroprotective effect of 
PDGF-BB on hippocampal neuron associated with inhibiting NR2B subunits of NMDA 
receptors [191]. Long-term treatment of 5-HT7 receptors leads to upregulation of PDGFβ 
receptors, which in turn provide a sufficient protection against NMDA receptor excitotoxicity in 
isolated hippocampal neurons [192]. Upregulation of PDGF ligands and PDGF receptors have 
been found in such neurological disorders associated with areas of neuronal cell death and 
excitotoxicity [116]. Thus, upregulation could promote to the neuroprotective effects of PDGFs 
and PDGF receptors via inhibiting Ca
+2
 influxes by NMDA receptors.  
 
Neurogenesis has been found to continue in the brain post-developmentally. Adult neurogenesis 
is restricted to dentate gyrus in hippocampus and olfactory bulb [193]. Other parts of the brain 
such as cortex do not have this ability [194]. Neurogenesis has a major role in maintaining the 
normal function of the hippocampus including learning and memory. Certain stimuli may 
increase neurogenesis including stress, ischemia, trauma, hypoxia, and neurodegenerative 
disorders [194]. Therefore, neurogenesis might serve as a neuroprotective mechanism in the 
brain. Recent studies demonstrated that the neuroprotection effect of neurogenesis in 
neurodegenerative disorders depends on the stage of the disease [194]. Four distinct stages are 
introduced for adult neurogenesis: proliferation from progenitor or stem cells, differentiation into 
immature neurons, development into mature neurons, and migration into neuronal network 
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including axon or dendrite targeting or synaptic integrating [194], or more simply, proliferation, 
differentiation, neuronal generation, and survival/functional neurogenesis [195]. At the early 
stage of neurodegeneration all the four stages of neurogenesis are increased. At the late stage of 
neurodegeneration the first three stages of neurogenesis are enhanced, however, the last stage is 
significantly impaired [194]. Thus, the effect of neurogenesis in neurodegenerative disorders is 
neurogenic stage-specific.  
 
Much of the evidence for neurogenesis in the context of neurodegrative diseases comes from the 
study of Alzheimer‟s disease. Abnormal proteolytic production of amyloid precursor protein 
(APP) results in formation of Aβ  which in turn promotes synaptic dysfunction and neuronal 
death. Massive accumulation of Aβ leads to formation of plaques [196]. Aβ is involved in 
initiating a neurodegenerative cascade that includes overactivation of glutamate and voltage-
sensitive calcium channels, leading to death of neuronal progenitor cells [196]. A significant 
increase in PDGF-BB has been observed in the brain of patient with Alzheimer disease [197]. 
Previously, our lab investigated whether the application of PDGF-BB could induce 
neuroprotective effects against Aβ-induced neuronal cell death; however, it failed to reverse the 
neurotoxicity induced by Aβ [154]. On the other hand, non-receptor tyrosine kinase Src and the 
small G-protein Rac1, downstream of PDGFβ receptor, can induce Aβ generation. So  the robust 
expression of PDGF-BB and PDGFβ receptors in neurodegenerative disorders might be further 
neuronal damage. However, transactivation of the PDGF receptors might be useful to transiently 
produce neuroprotection and pro-survival effects without inducing aberrant neurogenesis and 
degradation.  
 
Therapies for improving recovery after stroke are called neurorestorative therapies. 
Neurorestorative effects promote neurogenesis, angiogenesis, and neuronal and synaptic 
plasticity [198].  Growth factors such as hepatocyte growth factor (HGF) and glial cell line- 
derived neurotropic factor (GDNF) cause these effects. In addition, HGF has antifibrotic effects, 
which contribute to decreasing the formation of glial scarring [198].  However, these and other 
growth factors do not readily cross the blood-brain barrier. The administration small GPCR 
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agonists that transactivate PDGFβ receptors or other growth factor receptors could be a major 
step toward boosting in situ RTK activity and could provide an effective therapy in human 
stroke.  
4. Can GPCR ligands substitute for RTK ligands to achieve similar downstream effects 
such as neuroprotection? 
Despite the significant difference between phosphorylation profiles of the receptor between 
direct ligand and transactivated PDGF receptors, the activation level (as measured by specific 
phosphorylation sites) of downstream effectors were similar. This suggests that GPCR ligand-
induced transactivation could fully substitute for direct RTK activation. In addition, one 
important fact about the transactivation of PDGF receptors by GPCRs is that, because the 
pathways are intracellular, only the cells that express both the GPCR and the RTK would 
experience the effects of transactivation. For example, transactivation of PDGF receptors by D2- 
family dopamine receptor regulates NMDA currents. This process in the hippocampus depends 
on dopamine D4 receptors and in prefrontal cortex depends on dopamine D2 and D3 receptors 
[144]. 
 
To conclude, transactivation of RTKs via GPCRs is one mechanism to convey proliferative 
signals to cells. In the brain, transactivation of neurotrophic receptors (Trk receptors) via GPCRs 
leads to neuronal survival responses and neuronal differentiation (i.e., not proliferation) [199]. 
Transactivation could be a therapeutic approach to enhance adult neurogenesis in the early stages 
of Alzheimer disease to postpone or inhibit the neurodegenerative progression. In addition, 
transactivation could have a neuroprotective effects against NMDA excitotoxicity that occurs 
during stroke. Furthermore, the advantages of GPCR downstream cascades such as dopamine in 
parallel getting benefits of the neuroprotective effects of PDGF receptors by transactivation 
might be a useful approach in treatment of neurological disorders and neurodegenerative 
diseases.  
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Overall characteristics of GPCR-induced RTKs transactivation 
Various RTKs have similar downstream cascades, but what makes them unique involves the cell 
itself and the receptor involved. For example, Trk receptors, RTKs are activated via 
neurotrophins, are expressed primarily in CNS. Although activation of this receptor by 
neurotrophins results in neuronal differentiation, when Trk is ectopically expressed and activated 
in fibroblasts, it also increases proliferation similar to when the endogenous fibroblast growth 
factor receptors (FGFRs) are activated [200]. FGFs can induce proliferation in fibroblasts, but in 
CNS, they can mediate growth arrest and differentiation [201]. Thus, the same RTK can exert 
different effects depending on the cell type. In transactivation, the cell type and the distinct 
GPCRs and RTKs expressed will ultimately determine the physiological responses. As a whole, 
transactivation pathways described in the literature have several common intracellular signaling 
intermediates including phosphatidylinositol 3-kinases (PI3-kinase), Src kinases, calcium, and 
protein kinase (PKC). However, there are several differences reported in different pathways as 
well. For example, transactivation of the PDGF receptor via the dopamine D4 receptor is 
dependent on Gβγ but for dopamine D2 receptor is independent of Gβγ [24] and thromboxane A2 
receptor transactivation of the EGF receptor is dependent on cross-talk between Gq and Gi [202]. 
In CHO cells, transactivation of RTKs by GPCRs is dependent on Gi or Gβγ subunits [203]. 
 
Despite the results of this project, some important facts about signaling differences and 
similarities of PDGFβ receptors after direct activation compared to transactivated receptors must 
be considered. The fold change in phosphorylation of ERK1/2 and Akt, which are an important 
consideration for transactivation studies, must be evaluated precisely. It is important to consider 
whether activation of these PDGFβ receptor downstream effectors is independent of the 
downstream effects of GPCRs after transactivation. For this reason, ruling out the effect of 
GPCRs on ERK1/2 and Akt phosphorylation is essential. Using RTK selective kinase inhibitors 
is the most direct way to measure the dependency of ERK1/2 and Akt phosphorylation on GPCR 
activation. Another important fact that must be considered about transactivation is the specific 
responses of the cell to the distinct agonist of GPCR. In this case, the ligand for GPCRs, the 
specific GPCRs and RTKs express on the cell, and the intermediate effector and available 
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adaptor proteins could result in specific responses. For instance, in the SH-SY5Y cell line and in 
the CA1 hippocampus the transactivation of PDGFβ receptors by dopamine agonist such as 
quinpirole results in neuroprotection by regulating NMDA receptor currents; survival by 
activating Akt pathway and inhibiting GSK3β pathway; and proliferation by stimulating 
MAPK/ERK1,2 pathway. However, in the GH3 cell line (a rat pituitary epithelial-like tumor cell 
line), the application of quinpirole could results in anti-proliferative and apoptosis effects [207]; 
probably because of dopamine D2 receptor-induced transactivation of transforming growth 
factor-β (TGF-β) receptors which are associated with scaffold proteins containing effector 
proteins related to p38 MAPK pathway involving in oxidative stress and cell apoptosis.  
 
Because different phosphorylation profiles result in different downstream activation pathways, 
evaluation of all the Tyr phosphorylation residues of PDGFβ receptors for each specific GPCR 
agonist is essential for better understanding of the signaling profile after transactivation. 
Furthermore, the data from this project showed that neither phosphorylation profile nor 
downstream effectors of ligand-activated receptors versus transactivated receptors were similar. 
Since transactivation is initiated following activation of GPCRs by their ligands, regulatory 
effector proteins associated with GPCRs signaling could not only modulate GPCR downstream 
activity but might regulate transactivation mechanism as well. Understanding the exact 
regulatory mechanisms and regulatory effector molecules which are associated with 
transactivation modulation will help for better resolving the puzzles of this phenomenon. 
Moreover, disturbing the n-glycosylation linkage of the receptors and reduction of cell surface 
receptors could help to evaluate the effect of immature PDGFβ receptor on downstream effector 
proteins, which is another important fact in identifying signaling differences and similarities of 
direct activation compared to transactivation. Overcoming these limitations can help us to get a 
clearer overall conclusion for in vitro signaling differences and similarities in GPCR-induced 
transactivation of PDGFβ receptor and direct ligand activation. 
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 Chapter 5
Conclusion 
 
The results of this project showed that neither phosphorylation profile nor downstream effectors 
of ligand-activated receptors versus transactivated receptors were identical. Our data indicated 
that transactivation may result in RTK activation directed towards survival and proliferation 
pathways. These findings generally fit with previous work suggesting that transactivation of 
RTKs by GPCRs may be a mechanism for promoting cell survival.   
 
To conclude, the process of transactivation seems to be distinct from one receptor to another 
receptor. Any given receptor can exist in distinct conformational changes after associating with 
specific ligands that may determine which downstream cascades of the receptor are going to be 
activated and which are not. Phosphorylation of the RTK domain and subsequent protein-protein 
activation and interactions trigger downstream pathways in order to transmit signals to the 
nucleus. Various possible combinations of transactivation could exist depending on the cell type, 
the kind of GPCRs which are activated, the kind of RTKs to be activated, the relative abundance 
of RTKs in the cell, and the intermediate effectors that are available. Taken together, 
transactivation exists for integrating the complex signaling network between GPCRs and RTKs. 
It is a regulatory pathway for modulating downstream cascades of the both receptors since 
transactivation between GPCRs and RTK is a two-way interaction and both of the receptors can 
transactivate the other receptor type [133]. Furthermore, transactivation could control the 
activation of downstream cascades of RTKs by phosphorylating specific tyrosine residues. Thus, 
understanding the exact pathway for various transactivations and the physiological relevance for 
these could be helpful to treat various diseases. 
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Future directions 
Evaluating ligand-activated versus transactivated receptor by examining the tyrosine 
phosphorylation profile of each has provided very useful information. Since PDGFβ receptors 
also contain serine residues, investigating the phosphorylation of these sites and their association 
to downstream effectors of PDGF receptor is another important fact to be considered. For a 
better understanding of the effect of transactivation on the ERK1/2 and PI3 kinase/Akt pathways, 
an evaluation of all these pathways and their association with downstream cascades of dopamine 
receptors or PDGFβ receptors must be clarified. In addition, it remains unknown whether 
allosteric modulators for GPCRs will affect transactivation pathways in a similar manner as they 
affect classical G protein signaling pathways. Furthermore, using allosteric activators for GPCRs 
and evaluating their effect on transactivation might be result in using lower concentration of 
GPCR agonist for transactivation of RTKs. Finally, using high throughput screening may allow 
for the identification of specific GPCR ligands that preferentially promote transactivation.  
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